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The CRISPR/Cas9 system is one of the most popular technologies in 
biotechnology field over the last decade. The CRISPR system is derived from the 
bacterial immune system and now functions as a programmable nuclease and a 
genome engineering tool. These genome engineering tools are used not only to 
knockout genes but also knockin with exogenous DNA by causing DNA double 
strand break and cellular repair system. So far, original CRISPR system has a 
limitation that it is mainly used for knockout because it is focused on non-
homologous end joining (NHEJ) repair pathway rather than sophisticated 
homology directed repair (HDR).
However, about 58% of mutations known to cause human disease are point 
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mutations. Therefore, a technique for introducing a point mutation is required, and 
CRISPR RNA-guided base editors have recently been developed. CRISPR RNA-
guided base editors are fused form of catalytically inactive Cas9 (Cas9 nickase) 
and cytidine/adenosine deaminases. Cytosine base editors (CBEs) can induce C:G 
to T:A and, adenine base editors (ABEs) can deaminase adenosine and convert A:T 
pair to G:C pair. These base editor systems have recently been reported in different 
types independently and are being applied to bacteria, human cells, animals, and 
plants, but there has been little research on specificity of base editors, especially 
adenine base editors.
In this thesis, I will first show that the substitution frequency of the ABE can 
vary with codon usage and the number of nuclear localization signals (NLSs). Then, 
I will introduce a method for verifying the off-target effects of ABEs by modifying 
Digenome-seq method, which is known as DSB recognition method. Off-target 
effects of ABEs are different from those of Cas9 nucleases or CBEs. I also 
demonstrate whether these off-target effects actually occur in human cells. Finally, 
I show that using modified sgRNAs, highly specific Sniper Cas9 nickase instead of 
WT Cas9 nickase, and ribonucleoprotein delivery methods in lieu of plasmids 
delivery are effective to increase specificity of ABEs.
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Ⅰ. Introduction
The human genome project (Cantor, 1990), which began in 1990, ended in 
2003, faster than expected due to advances in sequencing technology and lower 
prices (Boeke et al., 2016). At last, it became possible to know the human 3.2 
billion base pair sequence. Since then, as postgenomic era, research on functional 
genomics has been carried out to study the roles of each gene and mutations that 
cause disease, rather than merely reading the nucleotide sequence (Eisenberg et al., 
2000). One of the most popular tools for studying this is the genome engineering
tool, or programmable nuclease. Genome engineering tools are divided into three 
generations: the zinc-finger nucleases (ZFNs), the transcriptional activator-like 
effector nucleases (TALENs) and the clustered regularly interspaced short 
palindromic repeat (CRISPR)-associated proteins 9 (Cas9) RNA-guided 
engineered nucleases (Kim and Kim, 2014).
ZFNs are proteins consisting of zinc finger proteins (ZFPs) at the N-
terminal and the catalytic domain of FokI restriction enzyme at the C-terminal 
(Kim et al., 1996). One finger motif of a ZFP recognizes 3-bp DNA sequences, 
usually 3-6 ZFPs linked to recognize 9-18 bp DNA. In addition, the catalytic 
domain of FokI acts as a dimer, so a pair of two ZFN units recognizes DNA that is 
5-7 bp away and cleaves DNA double strand (Bitinaite et al., 1998). 
The second tool, TALENs, is similar to ZFN in that it uses the catalytic 
domain of FokI as the nuclease domain. However, TALENs use the transcription 
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activator-like effectors (TALEs) derived from plant pathogenic Xanthomonas spp. 
bacterium as the DNA recognition domain (Boch et al., 2009; Moscou and 
Bogdanove, 2009). If the 12-13th amino acids of the repeat variable diresidues 
(RVDs) of TALEs are changed, they will recognize different DNA bases, and 
TALENs cleave the desired DNA target site as a pair (Boch et al., 2009; Moscou 
and Bogdanove, 2009). 
The last programmable nucleases are CRISPR/Cas9. The CRISPR system 
derived from the bacterial or archaeal immune system is a system that plays a role 
in removing foreign nucleic acids such as DNA and RNA to prevent the re-
infection of viruses (Barrangou et al., 2007; Makarova et al., 2006). The external 
nucleic acid is integrated into the repeat region on its bacterial own genome and is 
expressed in RNA form upon re-infection and acts with the related proteins to 
remove viral DNA or RNA. The most commonly used Type II CRISPR system 
consists of CRISPR RNA (crRNA) containing foreign DNA (protospacers), trans-
activating crRNA (tracrRNA), and Cas9 protein that can cleave DNA. The most 
widely used Type II Cas9 is derived from Streptococcus pyogenes (SpCas9). It has 
a role of cutting double strands of DNA (dsDNA) if contains a 20-nt 
complementary sequence of crRNA and a 5'-NGG-3 PAM (protospacer adjacent 
motif) sequence at 3 ' (Hsu et al., 2014; Jinek et al., 2012). In contrast to ZFNs or 
TALENs, which need protein engineering for other target sites, CRISPR/Cas9 can 
target to a variety of genomes if only a short RNA sequence is changed. Since the 
report that CRISPR is used as a programmable nuclease in vitro in 2012 (Jinek et 
al., 2012) and that it is applicable in human cell (Cho et al., 2013; Cong et al., 2013; 
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Hwang et al., 2013; Jiang et al., 2013; Jinek et al., 2013; Mali et al., 2013), related 
studies have increased rapidly, and in Science journal, it is called CRISPR 
revolution (Barrangou, 2014).
These programmable nucleases serve to cleave the DNA located in the 
desired region of the genome. When DNA double strand breaks occur in the cell by 
the programmable nucleases, they are repaired by the repair mechanism of the cell 
itself. There are two major methods: nonhomologous end joining (NHEJ) and 
homologous recombination (HR). NHEJ is predominant in the cell as a result of the 
ligation of the cleaved DNA without a repair template. However, it is prone to error, 
like small insertions or deletions (indels) and frame shift, usually resulting in gene 
knockout. HR is based on a template with a homologous sequence and is used to 
precisely correct mutations or insert genes in a sophisticated repair mechanism
(Chapman et al., 2012; Hsu et al., 2014; Kim and Kim, 2014; Liang et al., 1998).
In fact, genome engineering tools are used in a variety of fields such as 
genetic variation at the cellular level, making animal models, biofuel using algae, 
crop improvements as well as in the field of drug development and gene therapy
(Hsu et al., 2014; Shao et al., 2016; Zhang et al., 2018). Recently, clinical trials for 
cancer T cell therapy using CRISPR have been under way (Rodriguez-Rodriguez et 
al., 2019).
Cas9 cleaves DNA double strands with two nuclease domains, two of 
which are structurally RuvC and HNH domains (Nishimasu et al., 2014). The 10th 
aspartic acid (D10), which is an active site in the RuvC domain, cuts non-target 
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strand that are not complementary to sgRNA, and 840 histidine (H840) is active 
site of HNH domain playing role of cutting target strand binding sgRNA. Alanine 
substitution for each of these active residues (D10A or H840A) can no longer cut 
double-stranded DNA but works as a nickase that cuts only one strand (Jinek et al., 
2012; Nishimasu et al., 2014). These nickases can be used like nuclease by acting 
together as a paired nickase (Cho et al., 2014; Gopalappa et al., 2018; Ran et al., 
2013). When used in combination with a repair template, it is also used to improve 
HR efficiency without NHEJ-caused indels compared to wild type Cas9 nuclease
(Cullot et al., 2019; Satomura et al., 2017; Shao et al., 2018). Recently, it acts with 
the cytosine deaminase domain or the adenine deaminase domain, as a base editor. 
Dead Cas9, a catalytically impaired form (D10A H840A) that breaks down two 
active residues, can no longer cut DNA but still has the ability to bind to DNA, so 
it can be applied to a variety of applications. Transcription can be regulated by 
blocking transcription by binding to the region of the transcription start site
(Vigouroux et al., 2018), or by acting fused with the transcription repressor domain 
(Kruppel associated box (KRAB)) (Yeo et al., 2018), activator (VP64, p65)
(Chavez et al., 2015; Gilbert et al., 2014)). In addition, it can be fused with DNA 
demethylase (TET) (Xu et al., 2016), histone acetyl transferase (P300) (Hilton et al., 
2015), and deacetylase (HDAC) (Kwon et al., 2017) to enable epigenetic control, 
or with fluorescent proteins for labeling chromosome (Ma et al., 2016a) as well as 
with nuclear compartment-specific proteins for 3D genome re-organization (Wang 
et al., 2018a). Recently, it has been applied to researches such as biosensors (Koo 
et al., 2018; Lee et al., 2018a).
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One of the biggest limitations in the study using Cas9 is the low efficiency 
of HR. Since more than 50% of the mutations that can cause human genetic disease 
are point mutations (Rees and Liu, 2018), it is not enough to elaborate mutation to 
make a disease model or even to perform gene correction using Cas9 nucleases 
because HR efficiency is very low. The system that has been developed to 
supplement this is the base editor system which has been recently studied and 
which has received the most attention. In 2016, various cytosine base editors 
(CBEs) were reported and applied to several organisms; cytidine deaminases fused 
to Cas9 nickase or dead Cas9 (Gehrke et al., 2018; Hess et al., 2016; Jiang et al., 
2018; Kim et al., 2017b; Komor et al., 2016; Li et al., 2018b; Ma et al., 2016b; 
Nishida et al., 2016; Wang et al., 2018b). The cytidine deaminases used were 
human-derived activation-induced cytidine deaminase (hAID), sea lamprey-
derived PmCDA1, rat APOBEC1, and human-derived APOBEC3, which act on 
single stranded DNA (ssDNA) as well as single stranded RNA (ssRNA). These 
deaminases could target the C of non-target strand in R-loop formation. CBEs 
deaminate C, convert it to U, recognize it as T through base excision repair of the 
cell, and consequently convert C to T. 
While CBEs almost directly fused existing cytidine deaminases with Cas9, 
adenosine deaminases in adenine base editors (ABEs) system had to be changed 
through directed evolution (Gaudelli et al., 2017). Many types of cytidine 
deaminases act on ssDNA, but adenosine deaminases are not yet known to function 
effectively on ssDNA. To this end, TadA, the tRNA adenosine deaminases of 
Escherichia coli, was engineered to act on ssDNA. When TadA was fused to Cas9 
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dead form and it was functioned on ssDNA in E. coli, selection was made by 
screening system to preserve spectinomycin resistant colonies. Because TadA acts 
as dimer in general (Losey et al., 2006), TadA wild type, TadA mutant containing 
14 mutations produced through 7 rounds of directed evolution and Cas9 nickases 
fusion form was called ABE7.10. ABE7.10 was found to work well at various 
target sites without specific motifs at the human cell lines as well as in E. coli. The 
Cas9 nickases of ABEs nicks the target strand of the R-loop and the TadA 
heterodimer deaminates A of the non-target strand to inosine (I). During the cell 
repair, inosine is recognized as G by polymerase and thus A to G conversion occurs.
ABEs have also been reported to be applicable not only to the cell level but also to 
various animals, plants and so on (Kang et al., 2018; Li et al., 2018a; Liu et al., 
2018a; Liu et al., 2018b; Ryu et al., 2018).
An important issue when new CRISPR-based systems are developed is 
off-target effects. In order to apply to crop or livestock improvement or to see the 
therapeutic effect, it is necessary to identify and improve each Cas9 and sgRNA-
based off-targets. Many methods have been devised to identify the genome-wide 
off-targets of Cas9 nuclease: an integrase-deficient lentiviral vector (IDLV) capture
(Wang et al., 2015), high-throughput, genome-wide translocation sequencing 
(HTGTS) (Frock et al., 2015), direct in situ breaks labeling, enrichment on 
streptavidin, sequencing (BLESS) (Crosetto et al., 2013), breaks labeling in situ 
and sequencing (BLISS) (Yan et al., 2017), genome-wide, unbiased identification 
of DSBs evaluated by sequencing (GUIDE-seq) (Tsai et al., 2015), in vitro 
reporting of cleavage effects by sequencing (CIRCLE-seq) (Tsai et al., 2017), 
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selective enrichment and identification of tagged genomic DNA ends by 
sequencing (SITE-seq) (Cameron et al., 2017), and digested genome sequencing 
(Digenome-seq) (Kim et al., 2015). It is necessary to find a new off-target based on 
the fact that the base editors use a nickase rather than a nuclease and the efficiency 
varies depending on the position in the window of C or A. In the case of cytosine 
base editors, Digenome-seq was modified (Kim et al., 2017a). In vitro, genomic 
DNA was treated with CBE protein and one strand was cut and the other strand 
was cut with Uracil-Specific Excision Reagent (USER) enzyme (a mixture of E. 
coli Uracil DNA glycosylase (UDG) and DNA glycosylase-lyase Endonuclease 
VIII (Endo VIII)), which recognizes U, the deamination product of C, and aligned 
by whole genome sequencing potential off-target sites. 
Here, I sought to profile ABE off-target activity in the human genome
(Kim et al., 2019). First of all, I increased substitution efficiency of ABEs by 
optimizing codon usage and increasing the number of nuclear localization signals. 
Then, I present a modified version of Digenome-seq to assess genome-wide target 
specificity of ABEs. To produce DSBs at sites containing inosines, the products of 
adenine deamination, human genomic DNA is treated with an ABE7.10 protein-
guide RNA complex and either Endonuclease V (Endo V) or a combination of 
human Alkyladenine DNA Glycosylase (hAAG) and Endo VIII in vitro. 
Digenome-seq detects ABE off-target sites with a substitution frequency of 0.1% or 
more. As expected, ABE7.10, and BE3, a cytosine base editor, and unmodified 
Cas9 often recognize different off-target sites, highlighting the need for 
independent assessments of their genome-wide specificities (Kim et al., 2017a).
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Using targeted sequencing, we also show that use of preassembled ABE 
ribonucleoproteins, modified guide RNAs (Cho et al., 2014; Fu et al., 2014; Kim et 
al., 2015; Kim et al., 2016; Tsai et al., 2015), and Sniper-Cas9 (Lee et al., 2018b)
reduces ABE off-target activity and increases specificities in human cells.
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Ⅱ. Materials and Methods
1. Cell culture and transfection
HEK293T cells (ATCC CRL-11268) were cultured in DMEM medium   
supplemented with 10% FBS and 1% penicillin/streptomycin (Welgene) and 
verified using STR profiling. 
HEK293T cells (0.8 x 105) were seeded into 48-well plates 24 hours 
before transfection and transfected at 70–80% confluency with plasmids encoding 
ABE (750 ng of plasmid DNA), BE3 (750 ng), or Cas9 (750 ng) together with a 
plasmid encoding sgRNA (250 ng) using Lipofectamine 2000 (Invitrogen; 1.5 μL 
for each well). 
For ABE RNP-mediated genome editing, HEK293T cells (1 x 105) were 
electroporated with ABE7.10 protein (15 µg) and in vitro transcribed sgRNA (7.5
µg) or plasmids encoding ABE (0.6 µg) and sgRNA (0.2 µg) via a 10 µl Neon 
Transfection System with program number 15. 
Cells were lysed with lysis buffer (50 mM Tris-HCl, 1 mM EDTA, 0.005% 
SDS, pH 8.0) and DNA was amplified and analyzed after 72 hours post-
transfection.
2. Expression and purification of ABE7.10 protein
A plasmid encoding the human codon-optimized ABE7.10 with an N-
terminal His purification tag was transformed into BL21 Star (DE3)-competent E. 
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coli cells. Following transformation, a fresh single colony was grown overnight in 
Luria-Bertani (LB) broth containing 50 µg/mL kanamycin with shaking at 37 . 8 ℃
mL pre-cultures diluted at 1:50 were inoculated into individual flasks containing 
400 mL of LB broth supplemented with 50 µg/mL kanamycin; these cultures were 
incubated with shaking at 37  until OD℃ 600=0.65~0.70; thereafter, the cultures were 
kept on ice. Protein expression was induced with 1 mM isopropyl-b-D-1-
thiogalactopyranoside (IPTG; GoldBio), after which cultures were incubated for 16 
hours with shaking at 18 . ℃
The subsequent protein purification procedures were carried out at 4 . ℃
Cells were harvested by centrifugation at 6,000 xg for 10 minutes, and re-
suspended in lysis buffer (50 mM sodium phosphate (Sigma-Aldrich), 500 mM 
NaCl (Sigma-Aldrich), 10 mM imidazole (Sigma-Aldrich), 1% Triton x-100 
(Sigma-Aldrich), 20% glycerol, 1 mM 1,4-dithiothreitol (DTT; GoldBio), 1 mM 
phenylmethylsulfonyl fluoride (PMSF; Sigma-Aldrich), concentration of 1 mg/mL 
lysozyme (Sigma-Aldrich), 10 µM ZnCl2 (Sigma-Aldrich), pH 8.0). The 
suspensions were then alternatively incubated in liquid nitrogen and a water bath 
(37 ), repeated 3 times. Cells were lysed by sonication for 9 min℃ utes (5 seconds
(on), 10 seconds (off)), and the lysates were cleared by centrifugation at 15,000 xg 
for 20 minutes. The supernatant was incubated with nickel agarose beads (Ni-NTA, 
QIAGEN) for 60 minutes with shaking at 4 . The lysate℃ -resin mixture was loaded 
into a polypropylene column, washed 2 times with 3 column volumes of wash 
buffer (50 mM sodium phosphate (Sigma-Aldrich), 150 mM NaCl (Sigma-Aldrich), 
35 mM imidazole (Sigma-Aldrich), 20% glycerol, 1 mM DTT (GoldBio), 10 µM 
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ZnCl2 (Sigma-Aldrich), pH 8.0), and bound protein was eluted with elution buffer  
(50 mM sodium phosphate (Sigma-Aldrich), 150 mM NaCl (Sigma-Aldrich), 250 
mM imidazole (Sigma-Aldrich), 20% glycerol, 1 mM DTT (GoldBio), 10 µM 
ZnCl2 (Sigma-Aldrich), pH 8.0). The eluted protein fraction was next loaded into a 
polypropylene column that contained heparin agarose beads (Heparin Sepharose 6 
Fast Flow, GE Healthcare) and washed 2 times with 3 column volumes of wash 
buffer (50 mM sodium phosphate (Sigma-Aldrich), 150 mM NaCl (Sigma-Aldrich), 
20% glycerol, 1 mM DTT (GoldBio), 10 µM ZnCl2 (Sigma-Aldrich), pH 8.0). 
Bound protein was eluted with elution buffer (50 mM sodium phosphate (Sigma-
Aldrich), 750 mM NaCl (Sigma-Aldrich), 20% glycerol, 1 mM DTT (GoldBio), 10 
µM ZnCl2 (Sigma-Aldrich), pH 8.0). The resulting protein fractions ware 
concentrated with a centrifuge column (Amicon Ultra-4 Contrifugal Filter Devices, 
Millipore) at 6,000 xg.
3. In vitro transcription of sgRNAs
For a 100 μL in vitro transcription reaction, sgRNA templates containing 
T7 promoter sequence were incubated with each 4 mM NTP (rATP, rGTP, rCTP, 
rUTP), additional 14 mM MgCl2 and 100 units of RNase inhibitor (New England 
BioLabs), 500 units of T7 RNA polymerase (New England BioLabs) in T7 RNA 
polymerase buffer for 3 hours at 37℃. Subsequently, the reaction mixture was 
treated with DNase I (New England BioLabs) for 30 minutes at 37℃ and the in 
vitro-transcribed gRNAs were purified using an QIAGEN miRNeasy kit according 
to the manufacturer’s protocol.
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4. ABE7.10-mediated in vitro digestion of a PCR amplicon 
A PCR amplicon containing the HEK2 site was incubated with the 
ABE7.10 protein and in vitro transcribed HEK2-targeting sgRNA in a reaction 
volume of 100 μL for 1 hour at 37 °C. The deaminased product was then purified 
using a PCR purification kit (MGmed). 2 µg of deaminased product was incubated 
with Endonuclease V (40 units) (New England BioLabs) or human Alkyladenine 
DNA Glycosylase (10 units) (New England BioLabs) with Endonuclease VIII (20 
units) (New England BioLabs) in a reaction volume of 200 μL for 30 minutes at 
37 °C, after which the DNA was purified again using a PCR purification kit 
(MGmed) and subjected to analysis with a Bioanalyzer (Agilent) to determine the 
results of the in vitro digestion.
5. ABE7.10-mediated in vitro digestion of genomic DNA.
Genomic DNA was isolated from HEK293T cells using a DNeasy Blood 
& Tissue Kit (Qiagen) according to the manufacturer’s instructions. 8 μg of 
genomic DNA was incubated with the purified ABE7.10 protein (300 nM) and an 
sgRNA (900 nM) in a reaction volume of 400 μL in reaction buffer (50 mM Tris-
HCl (pH 8.0), 25 mM KCl, 2.5 mM MgSO4, 0.1 mM EDTA, 10% glycerol, 2 mM 
DTT, 10 μM ZnCl2) at 37 °C for 8 hours. The DNA was then purified with a 
DNeasy Blood & Tissue Kit (Qiagen) after removal of sgRNA using RNase A (50 
μg/mL). 3 μg of purified DNA was incubated with Endonuclease V (40 units) or 
human Alkyladenine DNA Glycosylase (10 units) with Endonuclease VIII (20 units) 
in a reaction volume of 200 μL at 37 °C for 2 hours, then was purified again with a 
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DNeasy Blood & Tissue Kit (Qiagen). Purified DNA was incubated with KAPA 
SYBR FAST qPCR Master Mix (Kapa Biosystems) and analyzed by real-time 
quantitative PCR (qPCR) to check for ABE7.10- and Endonuclease V- or 
ABE7.10-, human Alkyladenine DNA Glycosylase-, and Endonuclease VIII-
mediated DNA DSBs. The fraction of intact genomic DNA was measured using the 
comparative CT method (Schmittgen and Livak, 2008).
6. Whole genome sequencing and Digenome sequencing
1 μg of in vitro digested DNA was fragmented to the 400- to 500-bp range 
using the Covaris system (Thermo Fisher Scientific) and incubated with End 
Repair Mix (Illumina) to generate blunt ends. Fragmented DNA was ligated with 
adapters to produce libraries and subjected to WGS using a HiSeq X Ten 
Sequencer (Illumina) at Macrogen. WGS was performed at a sequencing depth of 
30–40×. Isaac aligner was used to map the genome sequence. DNA cleavage sites 
were identified using Digenome 1.0 and Digenome 2.0 programs. The source code 
of the version of Digenome 2.0 used in this manuscript is available at 
https://github.com/chizksh/digenome-toolkit2.
7. Targeted deep sequencing
On- and potential off-target sites were amplified using KAPA HiFi 
HotStart PCR polymerase(#KK2502). Amplicons were again amplified using 
TruSeq HT Dual index-containing primers to generate deep sequencing libraries. 
The libraries were sequenced using Illumina MiniSeq with paired-end sequencing 
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systems. Base editing frequencies indicate the frequencies of modified target sites 
with at least one edit within the editing window (position 4-7). The source code of 
the computer program to calculate substitution and indel frequencies are available 
at https://github.com/ibs-cge/maund.
8. Statistical analysis
All statistical results are means ± s.e.m. from three independent biological 
replicates. The significance of the differences between the two other groups was 
calculated using the two-tailed student's t-test method. One asterisk (*) indicates P 
< 0.05 in the figures and figure legends. Data were analyzed with Graph Pad 
PRISM 7 and Microsoft Excel.
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Ⅲ. Results 
1. Base editing efficiency according to the codon usage and 
the number of nuclear localization signals
ABEs consist of mutant Cas9 nickases and mutant E. coli TadA modified 
to deaminate DNA through directed evolution (Gaudelli et al., 2017). Therefore, 
various variants exist depending on the evolution stage. For example, there are 
ABE6.3, ABE7.8, ABE7.9, ABE7.10. First, I confirmed the substitution efficiency 
of these variants in two cell lines, HeLa and HEK293T. I cloned each TadA variant 
into Cas9 expressing plasmid vector, which we already have in our group, and 
compared it with the plasmids used in the reported paper (Gaudelli et al., 2017) and 
deposited on Addgene. Previous reports have shown that Cas9 expressing plasmid 
of our group has higher expression levels and induces higher mutation frequency 
due to codon usage than Cas9 plasmids in other groups (Kim et al., 2017c). In fact, 
we found that the efficiency of the variant construct based on Cas9 of our group 
was higher in HEK2, HEK3 and RNF2 target sites generally (Figure 1). In 
particular, the effect of the CMV promoter expressing the base editor was relatively 
weak in the HeLa cell line, so the effect was more dramatic (Mao et al., 2008). This 
result is in agreement with the previous paper that the expression level depending 
on the codon of the DNA encoding the base editors can affect the mutation 
frequency (Koblan et al., 2018; Zafra et al., 2018).
Among the variants of ABEs, the most widely used variant is ABE7.10, 
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which is the most efficient variant. There has been a report on ABEmax, a 
construct that has newly synthesized DNA encoding ABE7.10 and used a new 
codon and switched nuclear localization signals (NLSs) from one SV40 NLS to 
two Bipartite NLS (BpNLS) (Koblan et al., 2018). ABE (Broad) deposited in the 
Addgene, ABE (SNU), ABEmax (Broad), and ABEmax (SNU) constructs, which 
replaces one SV40NLS of ABE (SNU) with two BpNLS, were compared (Figure 
2a). Comparing the efficiency at 23 endogenous target sites, the base editing 
frequency was increased when the type and number of NLS were changed in both 
HEK293T cell line and HeLa cell line (Figure 2b-c, Table 1-2). The efficiency of 
ABEmax (SNU) was the highest in the HEK293T cell line (Figure 2b) and the 
ABEmax (Broad) efficiency was the highest in the HeLa cell line. Based on these 
results, it was confirmed that the codon usage and the number and type of NLS 
have a significant effect on the efficiency.
17
Figure 1. Comparison of substitution frequency using several versions of 
adenine base editors with different codon usages in HeLa and HEK293T cell 
line. Base editing efficiencies were measured by targeted deep sequencing. Means 
18
± s.e.m. were from three independent experiments. Student’s t-test (*: p<0.05, **:
p<0.01, ***: p<0.001, ****: p<0.0001)
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a
b                                  c 
Figure 2. Comparison of base editing frequency according to codon usages
and the number of NLSs in HEK293T and HeLa cell line. (a) Plasmid 
constructs for testing the efficiency dependent on the codon usage and the number 
of NLS. ABE and ABEmax are distinguished by the type and number of NLS. ABE 
contains only one SV40 NLS at C-terminal, and ABEmax contains two bpNLS at 
both the N and C termini. b, c, Base editing frequencies using 4 different ABE 
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constructs in HEK293T cell lines (b) and HeLa cell line (c). Total 23 target sites. 
Each dot represents the mean value of the results of the three independent
experiments. Base editing efficiencies were measured by targeted deep sequencing. 
Error bars indicate s.e.m. Paired student’s t-test (***: p<0.001, ****: p<0.0001)
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Table 1. Base editing frequencies of ABE7.10 depending on codon usage of 
vector constructs in HEK293T cell lines
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Table 2. Base editing frequencies of ABE7.10 depending on codon usage of 
vector constructs in HeLa cell lines
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2. Tolerance of ABE, BE3 and Cas9 for mismatched sgRNAs
a. Mismatch tolerance of ABE7.10 is independent of Cas9 
nucleases and BE3 cytosine base editors
I first investigated whether off-target activities of ABE7.10, BE3 (a 
cytosine base editor), and Cas9 are different from each other by testing a series of 
mismatched sgRNAs targeted to endogenous genomic loci (Figure 3a-c and Table 
3). To this end, I transfected HEK293T cells with plasmids encoding sgRNAs 
having one- to four-nucleotide mismatches and plasmids encoding human codon-
optimized ABE7.10, BE3, or SpCas9 and measured frequencies of single-
nucleotide substitutions or small insertions and deletions (indels) using high-
throughput DNA sequencing. As expected, base editors and Cas9 nucleases 
tolerated most of the single or double mismatches in the sgRNAs but were poorly 
active when combined with most of the sgRNAs having triple or quadruple 
mismatches. Notably, the tolerance of Cas9, ABE7.10, and BE3 for mismatched 
sgRNAs was often different from each other. For example, at the HEK3 site, Cas9 
complexed with an sgRNA having tandem mismatches at positions 3-4 (numbered 
1 to 23 in the 5’ to 3’ direction) was highly active, showing a relative activity of 66% 
compared to the fully-matched sgRNA, whereas ABE7.10 complexed with the 
same sgRNA was poorly active, showing a relative activity of 15% (Figure 3a). At 
the HEK2 site, several sgRNAs with 2~4 mismatches (indicated with asterisks in 
Figure 3c) were well-tolerated by ABE7.10 but were poorly active or inactive with 
Cas9 or BE3. Also, the overall correlation between ABE-mediated substitution 
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frequency and Cas9-mediated indel frequency or BE3-mediated substitution 
frequency was not always high, depending on the target site (Figure 4). These 
results suggest that ABE7.10, BE3, and Cas9 could recognize separate sets of off-
target sites in the human genome, calling for a method to determine genome-wide 







Figure 3. Tolerance of ABE7.10, BE3, and Cas9 for mismatched sgRNAs. 
Mismatched sgRNAs that differed from the HEK3 site (a), RNF2 (b), and HEK2 
site (c) by one to four nucleotides were tested in HEK293T cells. Base editing or 
indel frequencies were measured using targeted deep sequencing. Mismatched 
nucleotides and the PAM sequence are shown in red and blue, respectively. 
Asterisks indicate mismatched sgRNAs whose relative activity (mismatched 
sgRNA/matched sgRNA) with one enzyme is more than three times higher than 
that with the other two enzymes. Means ± s.e.m. were from three independent 
experiments.
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Table 3. Mutation frequencies of ABE7.10, Cas9, and BE3 at HEK3, RNF2, 
and HEK2 sites using mismatched sgRNAs
(Continued)
Base editing frequency (%) Indel frequency (%) Base editing frequency (%)
(+) ABE7.10 (+) Cas9 (+) BE3
GatttAGACTGAGCACGTGATGG 0.32 0.00 0.17
GGCCtgagCTGAGCACGTGATGG 0.41 0.03 0.13
GGCCCAGAtcagGCACGTGATGG 0.48 0.05 0.20
GGCCCAGACTGAatgtGTGATGG 0.31 0.09 0.12
GGCCCAGACTGAGCACacagTGG 0.39 0.02 0.25
GGtttAGACTGAGCACGTGATGG 0.33 0.02 0.15
GGCCCgagCTGAGCACGTGATGG 5.23 1.15 16.86
GGCCCAGAtcaAGCACGTGATGG 2.18 0.00 0.21
GGCCCAGACTGgatACGTGATGG 0.56 0.01 0.27
GGCCCAGACTGAGCgtaTGATGG 0.79 0.01 0.18
GGCCCAGACTGAGCACGcagTGG 1.54 0.18 0.22
GGttCAGACTGAGCACGTGATGG 6.02 49.87 2.11
GGCCtgGACTGAGCACGTGATGG 40.39 61.63 49.37
GGCCCAagCTGAGCACGTGATGG 12.81 58.23 6.68
GGCCCAGAtcGAGCACGTGATGG 15.88 46.57 12.28
GGCCCAGACTagGCACGTGATGG 17.80 19.65 3.98
GGCCCAGACTGAatACGTGATGG 0.46 0.04 0.19
GGCCCAGACTGAGCgtGTGATGG 3.63 1.66 0.64
GGCCCAGACTGAGCACacGATGG 9.28 0.51 1.53
GGCCCAGACTGAGCACGTagTGG 14.31 21.05 10.61
GaCCCAGACTGAGCACGTGATGG 50.32 62.84 67.85
GGCtCAGACTGAGCACGTGATGG 37.32 66.54 50.80
GGCCCgGACTGAGCACGTGATGG 39.21 76.56 74.92
GGCCCAGgCTGAGCACGTGATGG 41.09 63.21 71.77
GGCCCAGACcGAGCACGTGATGG 38.99 53.99 60.41
GGCCCAGACTGgGCACGTGATGG 64.05 57.72 72.00
GGCCCAGACTGAGtACGTGATGG 25.02 41.86 23.39
GGCCCAGACTGAGCAtGTGATGG 30.04 47.29 43.94
GGCCCAGACTGAGCACGcGATGG 48.08 61.45 66.11
GGCCCAGACTGAGCACGTGgTGG 43.88 60.87 72.75
GGCCCAGACTGAGCACGTGATGG 39.87 75.41 76.33






















Base editing frequency (%) Indel frequency (%) Base editing frequency (%)
(+) ABE7.10 (+) Cas9 (+) BE3
GctgcCTTAGTCATTACCTGAGG 0.13 0.01 0.27
GTCActccAGTCATTACCTGAGG 0.12 0.04 0.60
GTCATCTTgactATTACCTGAGG 0.12 0.01 0.11
GTCATCTTAGTCgccgCCTGAGG 0.10 0.02 0.20
GTCATCTTAGTCATTAttcaAGG 0.14 0.01 0.16
GTtgcCTTAGTCATTACCTGAGG 0.15 0.01 1.13
GTCATtccAGTCATTACCTGAGG 0.10 0.03 0.65
GTCATCTTgacCATTACCTGAGG 0.12 0.00 0.23
GTCATCTTAGTtgcTACCTGAGG 0.12 0.06 0.27
GTCATCTTAGTCATcgtCTGAGG 0.14 0.01 0.16
GTCATCTTAGTCATTACtcaAGG 0.10 0.01 0.20
GTtgTCTTAGTCATTACCTGAGG 1.22 12.77 47.48
GTCActTTAGTCATTACCTGAGG 0.22 0.23 15.33
GTCATCccAGTCATTACCTGAGG 1.44 7.76 34.05
GTCATCTTgaTCATTACCTGAGG 0.20 0.10 5.97
GTCATCTTAGctATTACCTGAGG 0.38 5.16 2.19
GTCATCTTAGTCgcTACCTGAGG 0.21 2.74 1.67
GTCATCTTAGTCATcgCCTGAGG 0.17 0.02 0.33
GTCATCTTAGTCATTAttTGAGG 0.14 0.02 0.13
GTCATCTTAGTCATTACCcaAGG 0.12 0.08 0.37
GcCATCTTAGTCATTACCTGAGG 18.06 46.51 65.55
GTCgTCTTAGTCATTACCTGAGG 14.01 49.31 70.67
GTCATtTTAGTCATTACCTGAGG 3.53 51.54 56.95
GTCATCTcAGTCATTACCTGAGG 9.98 41.89 62.12
GTCATCTTAaTCATTACCTGAGG 1.37 33.09 16.41
GTCATCTTAGTtATTACCTGAGG 23.31 43.94 60.08
GTCATCTTAGTCAcTACCTGAGG 4.99 29.11 25.20
GTCATCTTAGTCATTgCCTGAGG 11.45 35.75 36.77
GTCATCTTAGTCATTACtTGAGG 13.85 23.51 19.42
GTCATCTTAGTCATTACCTaAGG 8.98 27.32 31.08
GTCATCTTAGTCATTACCTGAGG 44.00 54.83 72.17





















Base editing frequency (%) Indel frequency (%) Base editing frequency (%)
(+) ABE7.10 (+) Cas9 (+) BE3
GggtgCAAAGCATAGACTGCGGG 1.33 0.03 4.53
GAACgtggAGCATAGACTGCGGG 12.76 30.83 15.00
GAACACAAgatgTAGACTGCGGG 6.48 0.30 1.18
GAACACAAAGCAcgagCTGCGGG 0.70 0.00 0.18
GAACACAAAGCATAGAtcatGGG 0.86 0.03 0.19
GAgtgCAAAGCATAGACTGCGGG 2.40 2.60 13.68
GAACAtggAGCATAGACTGCGGG 75.71 76.37 74.30
GAACACAAgatATAGACTGCGGG 22.45 0.64 7.76
GAACACAAAGCgcgGACTGCGGG 1.33 0.00 0.75
GAACACAAAGCATAagtTGCGGG 1.16 0.05 0.19
GAACACAAAGCATAGACcatGGG 5.12 0.02 0.52
GAgtACAAAGCATAGACTGCGGG 61.71 63.07 69.18
GAACgtAAAGCATAGACTGCGGG 57.23 73.27 75.35
GAACACggAGCATAGACTGCGGG 76.76 82.69 80.95
GAACACAAgaCATAGACTGCGGG 68.19 69.70 71.33
GAACACAAAGtgTAGACTGCGGG 77.93 45.78 76.05
GAACACAAAGCAcgGACTGCGGG 3.01 0.03 1.10
GAACACAAAGCATAagCTGCGGG 49.41 1.68 23.86
GAACACAAAGCATAGAtcGCGGG 53.12 0.96 14.18
GAACACAAAGCATAGACTatGGG 33.85 0.54 4.27
GgACACAAAGCATAGACTGCGGG 77.99 56.26 80.99
GAAtACAAAGCATAGACTGCGGG 77.47 56.28 81.51
GAACAtAAAGCATAGACTGCGGG 75.90 60.44 77.98
GAACACAgAGCATAGACTGCGGG 78.61 52.17 80.94
GAACACAAAaCATAGACTGCGGG 77.42 43.30 77.51
GAACACAAAGCgTAGACTGCGGG 75.62 53.51 81.23
GAACACAAAGCATgGACTGCGGG 67.88 11.14 66.25
GAACACAAAGCATAGgCTGCGGG 78.22 28.65 74.33
GAACACAAAGCATAGACcGCGGG 79.11 47.36 81.18
GAACACAAAGCATAGACTGtGGG 79.86 25.81 73.01
GAACACAAAGCATAGACTGCGGG 74.14 64.70 84.20

























Figure 4. Correlation between ABE-mediated substitution frequency and 
Cas9-mediated indel frequency with mismatched sgRNAs for HEK3 site(a), 
RNF2 (b), and HEK2 site (c). The blue dots indicate that the mismatched sgRNAs 
with which the ABE-mediated relative base editing frequencies are three times 
more efficient than Cas9-mediated relative indel frequencies or BE3-mediated 
relative base editing frequencies. The red color dots indicate that the mismatched 
sgRNAs with which the Cas9-mediated relative indel frequencies or BE3-mediated 
relative base editing frequencies are three times more efficient than ABE-mediated 
relative frequencies. 
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b. Mismatch tolerance of ABE according to the versions of 
TadA deaminase mutants
To identify off-target activities of other versions of ABEs, I transfected 
plasmids encoding sgRNA with one to four nucleotides mismatches and plasmids 
encoding ABE6.3, ABE7.8, ABE7.9, or ABE7.10 into HEK293T cell lines. In 
general, the base editing activity of ABE7.10 is known to be highest (Gaudelli et al., 
2017), so the base editing frequency was the highest with ABE7.10 using most 
mismatched sgRNAs, but there were some exceptions (Figure 5a). For example, 
when using sgRNAs with mismatches at positions 2-5 or 3-5, the activity of 
ABE6.3 was the highest (indicated with asterisks in Figure 5a). When checking the 
correlation-efficient value of each pair, I confirmed that ABE7.8 and ABE7.9 were 





Figure 5. Tolerance of ABE variants-induced base editing frequencies for 
mismatched sgRNAs. (a) Mismatched sgRNAs that differed from the HEK2 site 
by one to four nucleotides were tested in HEK293T cells. Base editing or indel 
frequencies were measured using targeted deep sequencing. Mismatched 
nucleotides and the PAM sequence are shown in red and blue, respectively. The red 
asterisks indicate more highly active mismatched sgRNAs with ABE6.3 versus the 
other ABE variants including ABE7.10. Means ± s.e.m. were from three 
independent experiments. (b) Correlation coefficients R2 value between relative 
frequencies of several ABE variants with mismatched sgRNAs targeting HEK2 site.    
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3. Digenome-seq to identify ABE7.10 off-target sites in 
human the genome
a. Digenome-seq workflow for the identification of genome-
wide ABE7.10 off-target sites
To identify genome-wide off-target sites of ABE7.10 via Digenome-seq, 
which relies on DNA double-strand breaks (DSBs) produced in vitro (Kim et al., 
2015), DSBs should be produced at sites containing inosine, which result from 
adenine deamination. Note that our group had previously used the recombinant 
BE3ΔUGI protein (BE3 with no UGI domain) and Uracil-Specific Excision 
Reagent (USER), a mixture of E. coli Uracil DNA glycosylase (UDG) and DNA 
glycosylase-lyase Endonuclease VIII (Endo VIII), to generate DSBs in vitro at sites 
containing uracil, a deamination product of cytosine, to identify genome-wide BE3 
off-target sites comprehensively in an unbiased manner (Kim et al., 2017a). 
Likewise, E. coli Endonuclease V (Endo V) or a combination of human 
Alkyladenine DNA Glycosylase (hAAG) and Endo VIII could be used to cleave a 
phosphodiester bond at inosine-containing sites (Figure 6a-c). Endo V recognizes 
inosine in DNA and catalyzes the cleavage of the second phosphodiester bond 3’ to 
the inosine, whereas hAAG excises hypoxanthine to yield an AP site 
(apurinic/apyrimidinic site), which is then recognized and processed by Endo VIII 
to induce a single-strand break. To test this idea, a PCR amplicon containing a 
target DNA sequence was first treated with the recombinant ABE7.10 protein 
expressed in and purified from E. coli (Figure 7) and its sgRNA to catalyze adenine 
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deamination in one DNA strand and to produce a nick in the other DNA strand 
(Figure 6), and then with Endo V (Figure 6b) or with hAAG/Endo VIII (Figure 6c) 
to yield a composite DSB. As expected, the PCR amplicon was cleaved by 
ABE7.10 plus Endo V (Figure 8a) or by ABE7.10 plus hAAG/Endo VIII (Figure 
9a).
Having confirmed that DSBs could be produced at ABE-targeted sites 
containing inosine using inosine-specific DNA repair enzymes, we next 
investigated whether human genomic DNA isolated from HEK293T cells could be 
processed in vitro with ABE7.10 plus Endo V or with ABE7.10 plus hAAG/Endo 
VIII for Digenome-seq analysis to identify genome-wide ABE off-target sites. 
Human genomic DNA was incubated with ABE7.10 ribonucleoprotein (RNP) (300 
nM ABE7.10 and 900 nM sgRNA) targeting an endogenous chromosomal site 
(known as HEK2) for 8 hours and then with the repair enzymes for 2 hours. Sanger 
sequencing was used to confirm ABE-mediated adenine-to-inosine conversion 
(inosine is changed to guanine during PCR amplification) at the target site (the 
opposite strand with a nick cannot be sequenced) and Endo V-catalyzed DNA 
cleavage at the inosine-containing site (a nicked DNA strand cannot be amplified) 
(Figure 8b). When genomic DNA is treated with both ABE7.10 and Endo V, the 
DNA strand containing inosine is cleaved by Endo V. Note that the DNA strand 
cleaved by Endo V cannot be amplified by PCR, whereas the DNA strand with no 
inosine is amplified. As a result, only adenine (and no guanine) is observed at the 
editing site by Sanger sequencing (Figure 8b). Quantitative real-time PCR were 
also used to verify targeted DNA cleavage using ABE7.10 plus Endo V (Figure 8c). 
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Similar results were obtained when hAAG and Endo VIII were used instead of 
Endo V (Figure 9b-c). The resulting digested genomic DNA samples were 
subjected to whole genome sequencing (WGS). After mapping sequencing reads to 
the human reference genome (hg19), alignments of sequence reads were monitored
at the on-target site using Integrative Genomics Viewer (IGV) and observed 
uniform rather than random alignments of sequencing reads, characteristic of a 
DSB (Figure 8d and Figure 9d). No such alignments were seen with untreated 
genomic DNA or genomic DNA treated with ABE7.10 alone (Figure 8d and Figure 
9d). These results suggest that Digenome-seq can be used for comprehensively 





b                               c
(By Daesik Kim in Institute for Basic Science)
Figure 6. Digenome-seq workflow for the identification of Genome-wide 
ABE7.10 off-target sites. (a) Overview of the Digenome-seq workflow for ABE-
mediated Digenome-seq. (b) Overview of Digenome-seq using ABE7.10. ABE7.10 
catalyzes the conversion of guanine to inosine. Endo V recognizes inosine and 
cleaves the second phosphodiester bond 3’ to the inosine. Arrowheads indicate the 
positions of phosphodiester bonds cleaved by the ABE7.10 nickase and Endo V. (c) 
ABE7.10 mediates adenine-to-inosine conversion in one strand and produces a 
nick in the other strand. hAAG excises inosine to produce an AP site and Endo VIII 
(DNA glycosylase and AP-lyase) cleaves the AP site. Arrowheads indicate the sites 
cleaved by the ABE7.10 nickase and hAAG/Endo VIII.
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(By Gyeorae Lee in University of Science and Technology)
Figure 7. SDS-PAGE analysis of ABE7.10 protein purification using nickel 
affinity chromatography and heparin bead chromatography. M: marker, I(-): 
cell lysate before IPTG induction, I(+): cell lysate after IPTG induction, S: soluble 
lysate fraction, IS: insoluble lysate fraction, FT: flow-through, W1, W2: waste after 
washing, Ni: Ni-NTA agarose beads after elution of bound protein, NE: protein
fraction eluted from nickel beads, Hp: Heparin Sepharose 6 Fast Flow affinity 
resins after elution of bound protein, HE: protein fraction after purification using 
heparin beads. The red box represents the ABE7.10 protein band. Similar results 
were obtained more than three times when the gel electrophoresis was repeated 
independently. 
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a                            b
c                           d
(By Daesik Kim in Institute for Basic Science and 
Gyeorae Lee in University of Science and Technology)
Figure 8. ABE7.10-, and Endo V-mediated Digenome-seq. (a) The PCR product 
containing a ABE7.10 target sequence was cleaved, when treated with both 
ABE7.10 and Endo V. Similar results were obtained more than three times when 
the gel electrophoresis was repeated independently. (b) Sanger sequencing results 
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showing A-to-G conversion by ABE7.10 and DNA cleavage by Endo V. (c) qRT-
PCR results showing DNA cleavage by the ABE7.10 nickase and Endo V. Means ± 
s.e.m. were from three independent experiments. (d) IGV images showing the 
alignments of sequence reads at the HEK2 target site obtained using WGS data.
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a                             b
c                             d
(By Daesik Kim in Institute for Basic Science and 
Gyeorae Lee in University of Science and Technology)
Figure 9. ABE7.10, hAAG, and Endo VIII mediated Digenome-seq. (a) A DSB 
occurs only when the PCR product is treated with ABE7.10, hAAG, and Endo VIII. 
Similar results were obtained more than three times when the gel electrophoresis 
was repeated independently. (b) Sanger sequencing results showing an A-to-G 
conversion when genomic DNA was treated with ABE7.10 and then a G-to-A 
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conversion when genomic DNA was treated with ABE7.10, hAAG, and Endo VIII. 
(c) qRT-PCR results showing digestion of genomic DNA by ABE7.10, hAAG, and 
Endo VIII. Means ± s.e.m. were from three independent experiments. (d) IGV 
images of the straight alignments of sequencing reads that are observed after 
treatment with ABE7.10, hAAG, and Endo VIII.
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b. Digenome-seq results reveal genome-wide off-target sites of 
ABE7.10
To determine ABE7.10 off-target sites in the human genome, a DNA 
cleavage score was assigned to each base-pair position across the entire genome
(Figure 10), using the WGS data, and listed all the sites with high scores (the initial 
cutoff score was set to 2.5 as done previously (Digenome 1.0)), corresponding to in 
vitro cleavage sites (Kim et al., 2016). Note that the Digenome 1.0 program does 
not consider sequence homology. 17 in vitro cleavage sites were obtained using 
Endo V or 18 such sites using hAAG/Endo VIII (Figure 11a-c). Importantly, 16 
sites, including the on-target site, were commonly identified by the two different 
experimental methods, showing that Digenome-seq is highly reproducible and 
reliable (Figure 11a-b). Sequence logos, obtained by comparing DNA sequences at 
these sites, showed that almost every nucleotide position contributed to the 
specificity of the ABE7.10 deaminase (Figure 11c).
   Next, Digenome-seq was performed with each of 6 additional ABE7.10 RNPs. 
A total of 7 sgRNAs in complex with ABE7.10 plus Endo V cleaved human 
genomic DNA at one to 28 (8 ± 4 per sgRNA, on average) sites including on-target 
sites (Figure 12 and Table 4 and 5). Note that our group had shown previously that 
Cas9 nucleases and BE3ΔUGI deaminases (plus USER) cleave genomic DNA at 
70 ± 30 sites (Kim et al., 2016) and 8 ± 3 sites (Kim et al., 2017a), respectively, in 
the human genome.  Among the 7 sgRNAs analyzed in this study, two sgRNAs 
had been combined with BE3ΔUGI and Cas9 and subjected to Digenome analysis 
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previously (Kim et al., 2016; Kim et al., 2017a), allowing direct comparisons 
between adenine and cytosine BEs and Cas9 (Figure 13a-b). The HEK2 sgRNA 
yielded 17, 2, and 35 in vitro cleavage sites when combined with ABE7.10, BE3, 
and Cas9, respectively (Figure 13c). The RNF2 sgRNA yielded 5, 1, and 13 sites 
with ABE7.10, BE3, and Cas9, respectively (Figure 13d). All of the 3 in vitro
cleavage sites identified using two BE3 deaminases were also identified using the 
respective ABE7.10 deaminases. By contrast, in vitro cleavage sites obtained with 
ABE7.10 and Cas9 were largely different. Thus, 10 out of 17 (= 59%) sites 
obtained with the HEK2 ABE7.10 were not identified using Cas9. 2 out of 5 (= 
40%) sites obtained with the RNF2 ABE7.10 were not identified using Cas9. These 
results suggest that ABEs are in general more specific than Cas9 but can recognize 
different sets of off-target sites. 
Then, ABE off-target base editing was validated at these 57 in vitro
cleavage sites identified above using the 7 sgRNAs via targeted amplicon 
sequencing. In addition, the Digenome 2.0 program was also used to identify many 
additional candidate off-target sites with a cutoff score of > 0.1, which contained 
PAM-like sequences (5’-NGN-3’ or 5’-NNG-3’) and had 10 or fewer mismatches, 
compared to the respective on-target sequences. 12 to 152 such sites (60 ± 20, on 
average) were obtained with the 7 sgRNAs complexed with ABE7.10, which 
included all of the 7 on-target sites and 57 in vitro cleavage sites obtained with 
Digenome 1.0 (Table 4 and 5). 
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(By Daesik Kim in Institute for Basic Science)
Figure 10. In vitro DNA cleavage scoring system for Digenome-seq analysis of 
ABE.
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(By Daesik Kim in Institute for Basic Science)
Figure 11. Genome-wide off-target effects of ABE using ABE7.10- and Endo V-
or hAAG and Endo VIII-mediated Digenome-seq (a) Genome-wide Circos plots 
represent DNA cleavage scores obtained via WGS using intact genomic DNA (gray) 
and genomic DNA treated with ABE7.10 plus Endo V (blue) or with ABE7.10 plus 
hAAG and Endo VIII (red). The red arrow indicates the on-target site. (b) A Venn 
diagram showing the number of in vitro cleavage sites in the human genome, 
identified using ABE7.10 plus Endo V or ABE7.10 plus hAAG and Endo VIII. (c) 
Sequence logos were obtained using WebLogo by comparing DNA sequences at 
Digenome-captured sites.
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(By Daesik Kim in Institute for Basic Science)
Figure 12. IGV images showing the straight alignments of sequencing reads at 
the RNF2, TYRO3, WEE1, EphB4, HPRT-exon6, and HPRT-exon8 sites.
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Table 4. The number of ABE7.10 on-target and off-target sites identified by
Digenome-seq
(By Daesik Kim in Institute for Basic Science)
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Table 5. Digenome-seq captured sites.
(Continued)
Chr Position DNA Cleavage Score DNA seq at a cleavage sites
HEK2_001 chr19 35505485 20.1 GAACAC-AAGCAcAGACTGaAGG
HEK2_002 chr15 93557679 15.1 GAACACA-tGCATAGACTGCTAG
HEK2_003 chr4 53536209 14.7 GAAtACtAAGCATAGACTcCAGG
HEK2_004 chr4 90522183 14.3 GAACACAAtGCATAGAtTGCCGG
HEK2_005 chr1 167742859 13.4 aAACACAgAGCAcAGACTGCTGA
HEK2_006 chr10 43159340 13.4 aAACACAAAGaCATAGACcaCTGG
HEK2_007 chr5 87240613 8.9 GAACACAAAGCATAGACTGCGGG
HEK2_008 chr9 290167 6.6 aAACAtAAAGaATAGACTGCAAG
HEK2_009 chr3 28560566 5.8 GAACACAAAGtATAGAaTGCTAG
HEK2_010 chr1 175310138 5.1 GgACACAAAGCtTAGACTcCAGG
HEK2_011 chr13 87616351 4.9 GAAgAtAAAGCATAGACTctAGG
HEK2_012 chr10 87125365 4.6 aAACAtAAAGCATAGACTGCaAAG
HEK2_013 chr18 32279782 3.9 aAAtACAAAGCATAGACTaatATG
HEK2_014 chr2 192248363 3.5 GAACACAtA-CATAGACaGCTGG
HEK2_015 chr5 160202385 3.0 GAAaACAAAGCAaAGAaaGCAGG
HEK2_016 chr15 63236612 2.9 aAcacaAtAGCATAGACTGgaCTG
HEK2_017 chr20 23101377 2.7 atACACAgAGCAaAGACTGCAGG
HEK2_018 chrX 48317375 2.5 aAACAtAAAGCcTAGACTGaCGG
HEK2_019 chr19 49972515 2.2 aAAaACAAAGCgTAGACTGtGGG
HEK2_020 chr12 81785997 2.1 GgACAaAAAGCATAGACTcaAGG
HEK2_021 chr1 40461424 2.1 atACACACAAGCAcAGACTGCAGG
HEK2_022 chr15 92968604 2.1 GAACACAgcaCATAaACTGCAGG
HEK2_023 chr5 142142325 2.0 aAACACtAA-CATAGACTGCAGG
HEK2_024 chr5 131174461 1.7 aAAtACAAtGCATAGACTGCTAG
HEK2_025 chr1 36097072 1.4 GtAaACAAAGCATAGACTGaGGG
HEK2_026 chrX 132724931 1.3 GAACA-tAAtCAcAGACTGCTGG
HEK2_027 chr6 139353017 1.3 ccAaACAAAaCATAGACTGCTGG
HEK2_028 chrX 36949816 1.3 GAAaACAAAaCATAGAgTGCTGG
HEK2_029 chr17 2670110 1.2 aAtCAaAtAGCATAGACTGCATG
HEK2_030 chr13 91254877 1.2 GAACACAAAcatagtACTGaAGG
HEK2_031 chrX 138877515 1.2 aAACAgAAAGCATgGACTGCGGA
HEK2_032 chr13 113428466 1.1 cAAtACAAAGgATAGACTGCAGG
HEK2_033 chr15 41796089 1.1 agACACAcAGCAcAGACTGCAGG
HEK2_034 chr11 128508576 1.0 GAAttCAAAGCATAGAtTGCAGG
HEK2_035 chr11 131870604 0.9 acACACAAAGCATAGACTatGTG
HEK2_036 chr4 91844238 0.9 GgAaACAAAGCATAGACattTGG
HEK2_037 chr3 105801924 0.8 tAAtACAAAGCATAGAtaGtTGG
HEK2_038 chr8 66280643 0.8 GAAtttAAAGCATAGACTGCAAG
HEK2_039 chr3 168165117 0.8 ctgaACAcAGCAaAGACTGCTGG




HEK2_041 chr9 97332608 0.7 GtAattAAAGCAcAGACTGCTGG
HEK2_042 chr3 33744669 0.7 GAAaACAAAcCAcAGACTGgGGG
HEK2_043 chr2 19474362 0.7 ctAttgcAAGCAcAGACTGCTGG
HEK2_044 chr16 64198277 0.7 GAAtACAtAaCATAGACTGgGGG
HEK2_045 chr1 199217096 0.7 atACcatAAGCATAGACTGtTGG
HEK2_046 chr22 28895717 0.7 attaAgAtAGCATAGACTGCAGG
HEK2_047 chr13 94827431 0.6 aAtgACtAAtaATAGACTGCTGG
HEK2_048 chr20 895768 0.6 atttcaAcAGCATAGACTGtAGG
HEK2_049 chr1 108869934 0.5 agtatagcAGCATAGACTGCAGG
HEK2_050 chr20 97640 0.5 GAAttCAAAGCATAGAtTGCAGG
HEK2_051 chrX 58256414 0.5 GcAttCtAAtaATAGACTGCTGG
HEK2_052 chr3 10835885 0.5 aAACACAtAGCAcAGcCTGCAGG
HEK2_053 chr8 97317606 0.5 GAACACAgtaCATAGACTGgCAG
HEK2_054 chr7 1973215 0.5 GgctgCctAGCAcAGACTGCCGG
HEK2_055 chr5 145405225 0.5 tctCctAccGCATAGACTGCTGG
HEK2_056 chr14 106066714 0.4 GtcgcaAAcGCATAGACTtCCGG
HEK2_057 chr2 34403831 0.4 cttattAAAGCAcAGACTGCTGG
HEK2_058 chr7 83764326 0.4 actatatAAGCATAGACTGtTGG
HEK2_059 chr14 106188442 0.4 GtcgcaAAcGCATAGACTtCCGG
HEK2_060 chr9 111564240 0.4 cgAtttcAAGCATAGACTGCTGG
HEK2_061 chr4 91393910 0.4 tAAtcatAAGCATAGAaTGCTGG
HEK2_062 chr9 117268271 0.4 GAAtAC-AAGCATAGACTGCTGT
HEK2_063 chr1 208174511 0.4 tcACAaAtAaGCATAGACTGgCGG
HEK2_064 chr6 164073518 0.4 cttgctAAAGCAcAGACTGCTGG
HEK2_065 chr18 56307002 0.4 aAgaACAAAaCATAGACTGCAGG
HEK2_066 chrX 119188148 0.4 aAttAaAcAGaATAGACTGCTGG
HEK2_067 chr10 11472312 0.4 GAACACAgAaCcATAGACTGgGGG
HEK2_068 chrX 93938357 0.4 aAACAaAAAGCATAGACcaCAAG
HEK2_069 chr3 33958845 0.4 GAACACA-gGCATAGACTatGGA
HEK2_070 chr9 90257919 0.4 ctcagagAAGCAcAGACTGCAGG
HEK2_071 chr2 144687377 0.4 atcatatAtGCATAaACTGCAGG
HEK2_072 chr1 191029339 0.4 cAACAaAAtatATAGACTGCTGG
HEK2_073 chr3 124241469 0.3 attgttAAAGCAcAGACTGCAGG
HEK2_074 chr11 80540770 0.3 agAtcttAAGCATAGACTGtGGG
HEK2_075 chr4 146455378 0.3 tAACACAAtacCATAGACTGgCGG
HEK2_076 chr6 70806985 0.3 GAAtACAAAtaATAGACTatTGG
HEK2_077 chr3 10539384 0.3 GAAtttAAAGCATAGACTctGGG
HEK2_078 chr13 80619390 0.3 aAACAaAtAaaATAGACTGCAGG
HEK2_079 chr5 126385455 0.3 ccACACcAAGCATAGACTtCTGG
HEK2_080 chr9 92683115 0.3 aAcaAaAcAGCATAGACTGCATG
HEK2_081 chr17 2810242 0.3 tAAttgcAAGCATAGACgGCAGG
HEK2_082 chr12 131431445 0.3 GgAgAgAgAGCATAGACTGCTGG
HEK2_083 chr11 105148271 0.3 agAaAtAAtatATAGACTGCAGG
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HEK2_084 chr1 75043747 0.3 tggttactAGCATAGACTtCAGG
HEK2_085 chr20 31946581 0.3 aAACACttAaCAcAGACTGCAGG
HEK2_086 chr8 58172690 0.3 ccACcagcAGCATAGACTcCAGG
HEK2_087 chr7 39877158 0.2 aAgacattttCATAGACTGtCGG
HEK2_088 chr3 65508026 0.2 tAAgcacAAGCATAGgCTGCTGG
HEK2_089 chr6 40925009 0.2 aAcaAgtAtGCATAGACTGCTGG
HEK2_090 chr15 81265977 0.2 aAAtACcAAcCAcAGACTGCAGG
HEK2_091 chr8 102768749 0.2 aAAtgCAtAGCATAGACTGCTGA
HEK2_092 chr1 237916998 0.2 tAACACAAAGacTAaACTGCAGG
HEK2_093 chr1 215323272 0.2 tAcCACgAAGCATAGACTGtAGG
HEK2_094 chr14 60249634 0.2 GAtCACtcAaCATAGACTGCATG
HEK2_095 chr3 29416510 0.2 GAACAg-AAaCATAGACcaaTGG
HEK2_096 chr11 79574188 0.2 tAcaAaAtAagATAGACTGCTGG
HEK2_097 chr10 96064388 0.2 acAgttAAAGaATAGACTGCAGG
HEK2_098 chr7 78443524 0.2 aAACACAAAgGCATAaACTcCAGG
HEK2_099 chr13 51093353 0.2 GAACACAcA-CAcAGACTGaGGG
HEK2_100 chr13 45266353 0.2 GgACAtAAAtCATAaACTGCTGG
HEK2_101 chr1 20011125 0.2 aAAgctAcAGCATAGACTGCAAG
HEK2_102 chr1 77190607 0.2 tcACACAAAcCATAGACTGaGGG
HEK2_103 chr11 68639975 0.2 GAtCtacctatATAGACTGCAGG
HEK2_104 chr9 31652144 0.2 tAtagaggAGCATAGACTGCTGG
HEK2_105 chr19 5068807 0.2 tAtCAgAAAGCAcAGACTGCGGG
HEK2_106 chr12 54405073 0.2 GAACAacAAGgATAaACTGCCGG
HEK2_107 chr12 33389548 0.2 tAcaAacAcGCATAGAaTGCCGG
HEK2_108 chr1 15519301 0.2 tAAgAaAtgGaATAGACTGCAGG
HEK2_109 chr20 21064111 0.2 aAAtAttAAGCATAGACTaCGGG
HEK2_110 chr20 17801623 0.2 GAAtgCcAAGCATAaACTGCAGG
HEK2_111 chr2 19844956 0.2 aActcCAAAGCATAtACTGCTGG
HEK2_112 chr2 116312126 0.2 GtgaACAcAGCATAGACTGgGGC
HEK2_113 chr15 35048979 0.2 atcCtaAgAaCATAGACTGCAGG
HEK2_114 chr11 19349648 0.2 tttgttAAAaCATAGACTGCTGG
HEK2_115 chr4 170242082 0.2 tAACAaAAtGCATAGACTGCTAG
HEK2_116 chr1 66454108 0.2 tgtataAcAGCATAcACTGCTGG
HEK2_117 chr9 20221246 0.2 aAACACtAAtaATAGACTGtGGG
HEK2_118 chr12 2617156 0.2 aAgCAatcAGCAcAGACTGCGGG
HEK2_119 chr19 32225924 0.2 GgACACAgAGtATAGACTGaGGG
HEK2_120 chr6 123554091 0.1 cAcaAatcAaaATAGACTGCTGG
HEK2_121 chr13 58440671 0.1 GAAttCAAAGCATgGACTGCAGG
HEK2_122 chr19 18370525 0.1 ttcCAaAAAaCATAGACTGCTGG
HEK2_123 chr8 74980814 0.1 GtAgAgtAAGCATAcACTGCTGG
HEK2_124 chrX 101465228 0.1 GgcCtttAgGCAcAGACTGCAGG
HEK2_125 chr21 16057037 0.1 aAgactttAGCATAGACTGCAAG
HEK2_126 chr5 76655640 0.1 GAAaAgtAAG-ATAGACTGCCGG
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HEK2_127 chrX 37275566 0.1 aActcatcAGCATAGACTGtAGG
HEK2_128 chrX 39813705 0.1 aAAtACAgAGCtTAGACTaCTGG
HEK2_129 chr3 99649762 0.1 aAACAtgAAGCATAGACaGCAAG
HEK2_130 chr3 86016290 0.1 acAtAgAtAttATAGACTGCTGG
HEK2_131 chr2 42080736 0.1 cAcattAAAGCAcAGACTGCTGG
HEK2_132 chr7 154994106 0.1 GAgCctAgAGCAcAGACTGCAGG
HEK2_133 chr10 85566693 0.1 aAgacttAAGCAaAGACTGCTGG
HEK2_134 chr1 176037520 0.1 ttACACAtAGCAcAGACTaCAGG
HEK2_135 chr7 56616286 0.1 agAagttAAGCATAGACTGgTGG
HEK2_136 chrX 69481649 0.1 ctAtAttgAGaATAGACTGCAGG
HEK2_137 chr17 79546106 0.1 GtgCACAcAGCATAGACTGCATG
HEK2_138 chr9 74099753 0.1 ctAgcaAAAaCATAGACTGCTGG
HEK2_139 chr7 113235709 0.1 tAAaACAAAGaAcAGACTGCTGG
HEK2_140 chr5 165353994 0.1 tAcagatAgtaATAGACTGCAGG
HEK2_141 chr5 134255399 0.1 aAttAatAAcaATAGACTGCTGG
HEK2_142 chr6 39115051 0.1 aAgattgcAGCATAaACTGCTGG
HEK2_143 chr10 732884 0.1 aAgCACAtAaCATAGACTGaAGG
HEK2_144 chr14 88566211 0.1 GtAgAaAAAGtATAGACTGCAGG
HEK2_145 chr14 89446986 0.1 tActAtggtGCATAGACTGCTGG
HEK2_146 chr11 133057022 0.1 ctctACtgAGaATAGACTGCAGG
HEK2_147 chr13 47277564 0.1 tgAaAtAAtaCATAaACTGCCGG
HEK2_148 chr6 42655828 0.1 aAtaAacttGCATAGACTGtAGG
HEK2_149 chr10 72922827 0.1 agACcCtAAGCATAGACTGCAGA
HEK2_150 chr16 55456878 0.1 tAcCcaAAtGCAcAGACTGCTGG
HEK2_151 chr2 194416373 0.1 aAgatagAtttATAGACTGCTGG
HEK2_152 chr4 177589824 0.1 aAACACAAAaCATAaAtTaCTGG
Chr Position DNA Cleavage Score DNA seq at a cleavage sites
RNF2-01 chr1 210858376 7.3 tcaccaTTAGTCATTACCTGCTG
RNF2-02 chr1 185056773 4.4 GTCATCTTAGTCATTACCTGAGG
RNF2-03 chr17 53928598 4.3 GTCATCTTAGTCATTAC-TGAGG
RNF2-04 chr6 143212078 4.1 GTaATaTTAGTCATTACCgGTGG
RNF2-05 chr17 17072075 3.6 GTCATCcTAGTCATTtaCTGGGG
RNF2-06 chr12 131619804 2.2 aTCAcCTTAGcCATTACCaGGGG
RNF2-07 chr9 102127746 1.4 GTCA-CTTAGTCATTgCCTGTGG
RNF2-08 chr15 92315580 1.0 GTCAcaTTAGcCATTACCTGTGA
RNF2-09 chr2 57559709 1.0 tgtATCTTAGaCATTACaTGTGG
RNF2-10 chr5 29673802 0.8 aTttTCTTAGTgATTAtCTGGGG
RNF2-11 chr15 25135467 0.8 catcTaaTAGTaATTACCTGGGG
RNF2-12 chr3 60339996 0.6 aTagTaTTAGTCATTACCTGTGA
RNF2-13 chr12 12595622 0.4 acCATCTTAGTCATTAtCTaATG




RNF2-15 chr2 51894204 0.4 aTCATCTTcaTCATTACaTGAGG
RNF2-16 chr2 134638146 0.4 cctATaTataTCATTACCTtTGG
RNF2-17 chr16 62531206 0.4 GTCATtTTAGTCATTAtCTtGAG
RNF2-18 chr22 44137982 0.4 aTCAcCTgAGTCATTACCcaTGG
RNF2-19 chr4 125521739 0.4 tTaATCTTAGTCATTACtTtTGG
RNF2-20 chr2 102668931 0.3 aTCATCaTcGTCATTAtCTGGGG
RNF2-21 chr14 88336132 0.3 aTCA--TTAGTCATTgCCTGAGG
RNF2-22 chr7 43967266 0.3 cTtAT-TTAGTCATTACCTGTAG
RNF2-23 chr2 41520178 0.3 GTCATaTTAaTCATTACaTaGAG
RNF2-24 chr1 111785389 0.3 tcCATCTcAcTCATTACCTGAGG
RNF2-25 chr8 51846780 0.3 GTtATCTTAGTCtTTACCTGAGA
RNF2-26 chr2 24749046 0.3 caCATCTTAccCATTACaTGAGG
RNF2-27 chr6 5869239 0.3 GcCAcCTcAGTCATTAgCTGGGG
RNF2-28 chrX 133138307 0.3 acatTagTAaaCATTACCTaGGG
RNF2-29 chr1 59227209 0.3 taCcTacctGTCATTACCTaTGG
RNF2-30 chr2 177556597 0.3 GatATCTTAGcCATTACCTaGGA
RNF2-31 chr3 113984053 0.3 tatcTacTAcTCATTACCTGAGG
RNF2-32 chr2 66353253 0.2 agCATCTctGTCATTACCcaGGG
RNF2-33 chr8 99451745 0.2 cgtgcaTTAGTCATTACCTGAGG
RNF2-34 chr5 109304296 0.2 GTCtgtaTAGTCATTACCTtTGG
RNF2-35 chr6 155177402 0.2 taCATCTatGTtATTACCTaTGG
RNF2-36 chr17 58390142 0.2 tTCATCTTtGTCATTACCTaAAG
RNF2-37 chr11 8498488 0.2 tatActaTAtaCATTACCTGGGG
RNF2-38 chr6 3726562 0.2 GctcatTcAcTCATTACCTaTGG
RNF2-39 chr16 5977420 0.2 GTgATCTaaAGTCATTACCTtAGG
RNF2-40 chrX 76946717 0.2 tTCAataTAaTCATTACCTGTGG
RNF2-41 chr18 62061226 0.2 aTtATtTTAGTCATTACCTtTGG
RNF2-42 chr19 14867049 0.2 ccCATCTcAGcCATTACCTGGGT
RNF2-43 chr13 70399620 0.1 agaATaTTAGTCcTTACCTGGGG
RNF2-44 chr12 86219647 0.1 GatcctTTAaTCATTACCTtTGG
RNF2-45 chr13 103624473 0.1 acCATCTTAGTCAcTACCTGGGC
RNF2-46 chr1 174478567 0.1 GTatTaTTgtaCATTACCTGAGG
RNF2-47 chr2 209871803 0.1 agCATCTTAGcCATTACCTcTAG
RNF2-48 chr5 91144278 0.1 agCATCTTAaTCcTTACCTcAGG
RNF2-49 chr4 160106364 0.1 GaatcCTcAtaCATTACCTGTGG
RNF2-50 chr4 37552932 0.1 aTCATCTTttTaATTACCTaTGG
Chr Position DNA Cleavage Score DNA seq at a cleavage sites
TYRO3-01 chr15 76553332 4.3 GGCCACACTAGtGTTGCcGCTGG
TYRO3-02 chr15 41857272 3.4 GGCCACACTAGCGTTGCTGCTGG
TYRO3-03 chr20 45312757 2.0 GGCCACACcAGCcTTGCTGtCGG




TYRO3-05 chr22 50686658 0.6 GGCCACACTgaCcTTGCTGCTGG
TYRO3-06 chr9 140109027 0.4 ttCCACAC-AGCtTTGCTGCTGG
TYRO3-07 chr17 17207899 0.3 GGCCAC-CTAGgGTTGCTGCTGG
TYRO3-08 chr11 99666699 0.2 ccaCcCtCTAGCaTTGCTGCTGG
TYRO3-09 chr11 27495183 0.2 cctaACACcAaCGTTGCTGCTGG
TYRO3-10 chr1 38684664 0.2 ctgagCtCTAGCaTTGCTGCTGG
TYRO3-11 chr3 22936710 0.1 GGCatataTAGCaTTGCTGCTGG
TYRO3-12 chr6 150629124 0.1 GaaCACACTAaCaTTGCTGtGGG
Chr Position DNA Cleavage Score DNA seq at a cleavage sites
WEE1-01 chr1 234241713 11.1 tTaGAGATGTTCTATTAtTCCGG
WEE1-02 chr11 9610086 2.0 GTCGAGATGTTCTATTACTCTGG
WEE1-03 chr4 18855558 1.9 GagGAGATGcTCTATTACTCCGG
WEE1-04 chrX 42756785 0.7 aTCaAGATGaaCTATTACTCTGG
WEE1-05 chr1 215805743 0.4 GTgGAGATGTTaTgTTACTCTGG
WEE1-06 chr5 57863350 0.4 GaCataATGTTCTATTACTCAAG
WEE1-07 chr4 119010382 0.3 taatAGATGTTCTATTACTaAGG
WEE1-08 chr15 80845387 0.3 aTtaAGATGTTCTATTAaTaGGG
WEE1-09 chr13 87867165 0.2 cagctaATGTaaTATTACTCAGG
WEE1-10 chr4 107037600 0.2 aTCaAGATaTTCTATTACTgGGG
WEE1-11 chrX 136297269 0.2 tcttAtATtTTCTATTACTCAGG
WEE1-12 chr1 8500986 0.2 aTaGAGcaGTTaTATTACTCTGG
WEE1-13 chr11 71806684 0.2 GTaGAGATGTTCTcTaACTCAGG
WEE1-14 chr12 83599167 0.2 cTCttttatTTCTATTACTCTGG
WEE1-15 chr8 71394697 0.1 aatataATaTTCTATTACTCAGG
WEE1-16 chr8 86942319 0.1 caactataaTTCTATTACTCTGG
WEE1-17 chr1 61165563 0.1 GgCtActgtcTCTATTACTCAGG
WEE1-18 chr20 45730192 0.1 aTttAGATaTTCTATTACTCTGA
WEE1-19 chr8 134795474 0.1 cTttAagataTCTATTACTCTGG
WEE1-20 chr2 128238175 0.1 caaGAGAcGcTCTATcACTCAGG
WEE1-21 chr7 31677975 0.1 aaacAGcTGTTCTATTACTCAGG
WEE1
Chr Position DNA Cleavage Score DNA seq at a cleavage sites
EphB4-01 chr7 100411300 10.3 GCAGAATATTCGGACAAACACGG
EphB4-02 chr5 81021421 8.0 GCAGAATATTaCaGACAAACtAGG
EphB4-03 chr15 47712791 4.1 GCAGAATATcaGGACAAACAATG
EphB4-04 chr11 123329727 2.4 aCAGAATATTCaGACAAtCACAG
EphB4-05 chr1 93047514 2.2 GCAGtA-AaTaaGACAAACAAGG
EphB4-06 chr15 51198151 1.9 aCAaAATATTCGGACAggCACGG
EphB4-07 chr18 29712895 1.8 GCAGAATtTaaGGACAAgCAAGG




EphB4-09 chr13 25919264 1.4 cagtAATATTCaGACtAAACATGG
EphB4-10 chr3 122057177 0.9 ttAatATATaaGGACAAACATGG
EphB4-11 chr1 26891812 0.8 aCAtAATATTCaaACAAACAGGG
EphB4-12 chr10 131074805 0.6 aatGAATAaagGGACAAACAGGG
EphB4-13 chr4 123425007 0.5 tCAG-ATATaaGGACAAACATGG
EphB4-14 chr5 60692862 0.4 GCtGAATATTgGGACAAtCATGG
EphB4-15 chr9 930844 0.4 GCAGttATAaaaaGACAAACAGGG
EphB4-16 chr9 29344386 0.4 aCAGAATATaaGaACAAAtATGG
EphB4-17 chr4 160752620 0.4 atAGAATAaTCaGACAAAaAAGG
EphB4-18 chr16 23706770 0.4 GCAG-ATAaagGGACAAACATGG
EphB4-19 chr11 117354211 0.3 GacagtgAaTaGGACAAACATGG
EphB4-20 chr14 90497703 0.3 tgAGAATATgCGGACAAACACAG
EphB4-21 chr2 68459706 0.3 atAGAATATTaGGACAAAtAGAG
EphB4-22 chr13 51951355 0.2 caAtAATAaaaGGACAAACATGG
EphB4-23 chr17 7777056 0.2 aCAGgATAaaaGGACAAAtATGG
EphB4-24 chr3 188431448 0.2 aCAGAtATAcgtaGACAAACAGAG
EphB4-25 chr12 11705824 0.2 atAGAATAagaaGACAAACATGG
EphB4-26 chr10 95697506 0.2 ttAGAATATTCctACAAACAAGG
EphB4-27 chrX 123665071 0.2 cCAtgtTATTCaGACAAACATGG
EphB4-28 chr16 75869847 0.2 GCAGAA-AaTaGGACAAtCACGG
EphB4-29 chr6 128784409 0.2 agAGAATATa-GGACAAACtTGG
EphB4-30 chr5 144297821 0.2 GCAGAAataTttGACAAACAAGG
EphB4-31 chr14 29760524 0.1 aaAGAATATa-GaACAAACAGGG
EphB4-32 chr1 36914336 0.1 aCAGAA-ATaCGaACAAACATGG
EphB4-33 chr21 26227853 0.1 aacaAATgcaaGGACAAACATGG
EphB4-34 chr13 63528393 0.1 aCActAT-TTaaGACAAACAGGG
EphB4-35 chr10 72516747 0.1 aCAGAActacgaGACAAACACGG
EphB4-36 chr7 20108292 0.1 GCAGA-TAccCaGACAAACAGGG
EphB4-37 chr1 89896856 0.1 taAGAATAT-aGGACAAACAGGA
EphB4-38 chr4 145533104 0.1 cCAGAATATTa-GACAAACATGG
EphB4-39 chr20 9784096 0.1 agAGAATATagGGACAAAtAAGG
Chr Position DNA Cleavage Score DNA seq at a cleavage sites
HPRT_E6-001 chrX 133627607 29.0 GTATAATCCAAAGATGGTCAAGG
HPRT_E6-002 chr12 7468915 21.3 GTATAcatCcAAGATGGcCAGGG
HPRT_E6-003 chr3 10057621 17.0 GTATtA-CCAAAGATGGTCtGGG
HPRT_E6-004 chr22 39586062 12.7 GTATAATC-AAAGATGGcCcTGG
HPRT_E6-005 chr7 13928792 10.5 GTATtAT-CAAAaATGGTCAAGG
HPRT_E6-006 chr1 225831201 10.2 aTATAA-CCAAAGATGtTCACAG
HPRT_E6-007 chr17 53575925 9.3 aTATAATCttAAGATGGTCAAGG
HPRT_E6-008 chr12 13406973 9.0 aTATAATCCtAAGATGtTCATGG




HPRT_E6-010 chr7 85914581 5.6 aTAcAATCCAAAGtTGGTCtGGG
HPRT_E6-011 chr3 9906633 4.7 aTATAttaCCAAAGATGGTCtGGG
HPRT_E6-012 chr8 125496169 4.5 GTAgAATCCAtAGATGGaCAGGG
HPRT_E6-013 chr17 10064482 4.3 GTATtA-CCAAAGATGGTCATGG
HPRT_E6-014 chr2 53374352 4.3 GTAcAATCaAAAGATGaaCAAGG
HPRT_E6-015 chr4 102026801 4.1 aTATtATCCAAAGATGGagtTGG
HPRT_E6-016 chr6 19070067 3.8 aTgTAtTCCAAAGATGGTCAGGG
HPRT_E6-017 chr6 7761387 3.7 aagTAATCCAAAGATaGTCtTGG
HPRT_E6-018 chr12 59613203 3.6 GTATAAcCCAAAGAaaGTaATGG
HPRT_E6-019 chr16 20336811 3.6 aTATAtATtCcAAGATGGTtcTGG
HPRT_E6-020 chr4 136809212 3.5 tTATAATCCAAAGAaGGcCAAGG
HPRT_E6-021 chr12 117915656 3.5 GTATctAcCCAAAGATGtTCATGG
HPRT_E6-022 chr14 45005861 3.4 GTATAAT--AAAGATGGTCAAGG
HPRT_E6-023 chr14 104033102 3.3 aTAgAtTCCAAAGATGGaCATGG
HPRT_E6-024 chr11 93731924 3.1 cTATAATCtAAAaATGGTCAAGG
HPRT_E6-025 chr13 75257165 2.9 GTATAtTagAAAGATGGTCATGA
HPRT_E6-026 chr15 54911620 2.8 GgATAATCaAAAGATGGaCtTGG
HPRT_E6-027 chrX 6849511 2.6 aTATAATgCAAAGcTGGTCACGG
HPRT_E6-028 chr11 87526371 2.5 aTAcAATCCAAAGATatTCtAGG
HPRT_E6-029 chr3 19652583 2.4 GTATAATCCAAAGgTGGcCtAGG
HPRT_E6-030 chr17 45009128 2.4 aTATAATCCAtAGAaGGTCAAGA
HPRT_E6-031 chr8 9090663 2.3 GatatAatacAAGATGGaCAAGG
HPRT_E6-032 chr12 6810501 2.2 GgATAATCCAAAGATGGTgcAAG
HPRT_E6-033 chr6 118233456 1.5 aTATAAaCCAAAGATcGTtAAGG
HPRT_E6-034 chr14 85667729 1.4 tctcccTCCAAAGAaGGTCACGG
HPRT_E6-035 chrX 110551547 1.4 tTATAgTCCAAAGgaaGTCAGGG
HPRT_E6-036 chr8 18630339 1.2 tatTtATCCAAAGATGGTCtAGA
HPRT_E6-037 chr12 45338334 1.1 aTATAtaCCAAAGgTaGTCATGG
HPRT_E6-038 chr7 135056752 1.1 aggagATCCAAAGATGGTCAAGG
HPRT_E6-039 chr9 82090375 1.1 acATAgTCCAAAtATGGaCAGGG
HPRT_E6-040 chr12 103187212 1.0 GTATAtAattcAAGATGGTCAGGA
HPRT_E6-041 chr12 58996606 1.0 GaATAAgCCAAAGATGGTCAGTG
HPRT_E6-042 chr12 49657468 1.0 GTATctcCCAgAGATGGTCAAGG
HPRT_E6-043 chr7 120024149 0.9 aTgTAATCtAAAGATGaTtATGG
HPRT_E6-044 chr15 101375955 0.9 GTATAA-CCAAtGATGGTCAGGA
HPRT_E6-045 chr10 13873222 0.9 aTgTcATCCAAAGAaGGTCAGAG
HPRT_E6-046 chr21 41428166 0.9 agATAtTCCAAAGATGGTgAGGG
HPRT_E6-047 chr1 7314483 0.8 tTtccAcCCAAAGATGGTCcAGG
HPRT_E6-048 chr8 133182863 0.8 tTATAgctCcAAGATGGTCAAGG
HPRT_E6-049 chr6 1253997 0.8 tcAgAATCCtAAGATGGTCAGGA
HPRT_E6-050 chr12 15783424 0.8 GgATAATCCAAAGtTGGTCATAG
HPRT_E6-051 chr9 15160111 0.7 GTATAATCC-tAGATGGTgAGGG
HPRT_E6-052 chr12 29153372 0.7 GTATttTCCAAcGATGGTCATGG
59
(Continued)
HPRT_E6-053 chr3 1123204 0.7 GaATAATtCAAAGATaaTCAAGG
HPRT_E6-054 chr2 50999543 0.7 aaATAATa-AAAGATGGTCATGG
HPRT_E6-055 chr2 36768513 0.7 cTcatATCCAAAGATGGTaAAGG
HPRT_E6-056 chr6 4210565 0.7 tTATAA-CCAAAGATGGTaATGG
HPRT_E6-057 chr14 48260581 0.7 GccTAATCCAAAGATGagCAGGG
HPRT_E6-058 chr8 117575569 0.7 cTATAATgCCAAAGATGGTCATGG
HPRT_E6-059 chr5 160988739 0.7 GTATAgatCAAAGATGccCACGG
HPRT_E6-060 chr14 94364216 0.6 tctcctTCCAAAGATGGTCtGGG
HPRT_E6-061 chr9 125328946 0.6 aTAatcTCCAAAGATGtTCAGGG
HPRT_E6-062 chr9 134083092 0.6 aTATttTCCAAAGATGaTCACAG
HPRT_E6-063 chr16 6159271 0.6 tatTgATCCAAAGATGaTCAAGA
HPRT_E6-064 chr22 27822987 0.6 aTATAtTtCcAAGATGGgCAGGG
HPRT_E6-065 chr19 48640167 0.6 tTcTcATCCAAgGATGGTCAGGG
HPRT_E6-066 chr11 107913428 0.6 aTATAAaCaAAAGATGGTttAGG
HPRT_E6-067 chr22 25519897 0.6 aaATAgTCCAAgGATGGcCAGGG
HPRT_E6-068 chr2 222954701 0.5 GTATttTCtAAAGATGGTCATGA
HPRT_E6-069 chr1 21736973 0.5 GgATAAatCcAAGtTGGTCATGG
HPRT_E6-070 chr20 41218527 0.5 aTATttTCCAAAGATGGTCATGA
HPRT_E6-071 chr16 55855323 0.5 tgActcTCCAAAGATGGTCACAG
HPRT_E6-072 chr3 39725483 0.5 caATAtTCCAAAGATGGTtATGG
HPRT_E6-073 chrX 141390834 0.5 GcAgcATCCAAAGATGGgCAGGG
HPRT_E6-074 chr4 23070418 0.5 cTATAATtCAAAGATGtTCtTGG
HPRT_E6-075 chr8 9653862 0.5 cacatATatAAAGATGGTCATGG
HPRT_E6-076 chr22 32085052 0.5 GTATctTCCAAAGATGGcCAATG
HPRT_E6-077 chr16 8011143 0.5 aatattaCCtAAGATGGTCATGG
HPRT_E6-078 chr13 21574593 0.5 GTATAAaCCAAAaATatTCAGGG
HPRT_E6-079 chr12 58995581 0.4 GaATAAgCCAAAGATGGTCAGTG
HPRT_E6-080 chr10 107263858 0.4 aTATAATgCAAAGAaaGTCAAAG
HPRT_E6-081 chr11 44024764 0.4 GTATAAgCCAAAGcaGGTCACGG
HPRT_E6-082 chr6 138575959 0.4 aTATAAaCCAAAGAcGGcCcTGG
HPRT_E6-083 chr3 98960373 0.4 agATAATCCAAgGATGGTagAGG
HPRT_E6-084 chr8 43181791 0.4 aTATAATCCAgAaATGtTCACGG
HPRT_E6-085 chr5 118103678 0.4 actcttTtCcAAGATGGTCAGGG
HPRT_E6-086 chr7 129222414 0.4 cTgatgTCCAAAGATGGTCtCGG
HPRT_E6-087 chr3 160736673 0.4 GTgaAtTCCAAAGAaGGTCATGG
HPRT_E6-088 chrX 125678217 0.3 catTAATCCAAAGATGaTaAAGG
HPRT_E6-089 chr6 152915585 0.3 GctctATCCAAAGATGGaCAGGG
HPRT_E6-090 chr9 128839841 0.3 cTgTAATCCAgAaATaGTCAGGG
HPRT_E6-091 chr14 96980434 0.3 GTATAtgTCCAAAGATGaTCATGC
HPRT_E6-092 chr13 80168480 0.3 cTATAATCCAAgGAaGGcCAAGG
HPRT_E6-093 chr8 74179696 0.3 GTATccTCCAAAGATGagtAAGG
HPRT_E6-094 chr4 112559644 0.3 aaATAATaCAAAGATGGTtgGGG
HPRT_E6-095 chr13 74505576 0.3 caATAATCCAAAGAaGaTtAAGG
60
(Continued)
HPRT_E6-096 chr19 32267421 0.3 aTATAATCaCAAAGATGGcaATGG
HPRT_E6-097 chr14 95877075 0.3 GTtTAAgCCAAAGtTGGTCgGGG
HPRT_E6-098 chr8 36263307 0.3 GTAgcATCCAAAGATGGTggAGG
HPRT_E6-099 chr5 28287911 0.3 GTAgAATatcAAGATGGTCAAGG
HPRT_E6-100 chr5 98310114 0.3 agAatgcCCtAAGATGGTCtGGG
HPRT_E6-101 chr6 76199451 0.3 aTATAAcCagAAGATGtTCATGG
HPRT_E6-102 chr10 83966021 0.3 GTATtATCtAAAGgaGGTCATGG
HPRT_E6-103 chr1 55051337 0.2 agATAtaCagAAGATGGTCgGGG
HPRT_E6-104 chr8 91475188 0.2 aaATAATCCAAAaATaGTCATGG
HPRT_E6-105 chr9 20225753 0.2 cTtTAtTCCAAAGATaGTCATGG
HPRT_E6-106 chr6 81303564 0.2 GcATAttTCCAAAcATGGTCAAGG
HPRT_E6-107 chr1 241707903 0.2 GTATttTtCAAAGATGGTCATGA
HPRT_E6-108 chr9 28194167 0.2 GTATttTCCAAAGATGGcCACGA
HPRT_E6-109 chr3 17000484 0.2 tataAATCCAAgGATGGTCtGAG
HPRT_E6-110 chr16 73853834 0.2 tTATttTCCAAAGATGGTCACGA
HPRT_E6-111 chr15 29999660 0.2 tgcacATCCAcAGATGGTCAGGG
HPRT_E6-112 chr5 157715478 0.2 GTgTAATCCAgAGATGaTCACAG
HPRT_E6-113 chr10 2711644 0.2 tctTAATCCAtAGAaGGTCAAGG
HPRT_E6-114 chr17 61689903 0.2 tTcaAAT--AAAGATGGTCACGG
HPRT_E6-115 chrX 125134402 0.2 tcATAATCCAAAaGATGGaCAGGG
HPRT_E6-116 chr1 94251248 0.2 aTATAATaCAAAataGGTCAGGG
HPRT_E6-117 chr22 35100488 0.2 cTAgAtaCCAAAGATGGTCAGAG
HPRT_E6-118 chr2 38407889 0.2 aTtTAgTCCAAAGAgGGTCAGAG
HPRT_E6-119 chr7 112015061 0.2 aTATAcAaCCAAAGATGtTCtAGG
HPRT_E6-120 chr20 2163127 0.2 GTATAtAcatAAAGAaGGTCATGG
HPRT_E6-121 chr8 100230333 0.2 aTtatATCCAAAtATGGTCAGAG
HPRT_E6-122 chr2 206041685 0.2 tTATAATCCAtAAaATGGTCATAG
HPRT_E6-123 chr1 153531237 0.2 tTAgtcTCCAAAGATGGTCACTG
HPRT_E6-124 chrX 118562021 0.2 tatcttTCCAAAGATGGTCtATG
HPRT_E6-125 chr10 26718853 0.2 GTATttTCCAAAGcTaGTCATGG
HPRT_E6-126 chr17 61180425 0.2 GcATAATCCAAgGAaGGTCcTGG
HPRT_E6-127 chr2 125810813 0.2 aTATttTCCAAAaATGGTCACAG
HPRT_E6-128 chr7 28299854 0.2 aTATAATCCAAAagaaGgaAAAG
HPRT_E6-129 chr11 23995596 0.1 aTATAtcCaAAAGATGGTCtGGA
HPRT_E6-130 chr1 34307709 0.1 GatattaaCAAAGATGGTCtGGG
HPRT_E6-131 chr5 173751304 0.1 GaAgAATCCAAcGATGGcCACGG
HPRT_E6-132 chrX 14442705 0.1 acATAATCaCAAAtATGGTCACGG
HPRT_E6-133 chr20 15867186 0.1 GTATttTCCAAAGATGGcCACAG
HPRT_E6-134 chr5 157484648 0.1 tctaAtgaatAAGATGGTCgAGG
HPRT_E6-135 chr1 203269364 0.1 agATAATgCAAAGAcGGTtAGGG
HPRT_E6-136 chr12 28980303 0.1 GTATAtaCCAAAaATGGTgAAGG
HPRT_E6-137 chr18 52818481 0.1 aTATAc-CCAAAGATGGTCcAAG
HPRT_E6-138 chr10 131217430 0.1 tctgAcTCCcAAGATGGTCtTGG
61
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HPRT_E6-139 chr3 109018997 0.1 GgAgAtaCCAAAGATGGTCAGGA
HPRT_E6-140 chr21 20933404 0.1 GTATAtTtCAAAtATGGTCATAG
HPRT_E6-141 chr2 220647283 0.1 aTATAA-CCAAAGATtGTCAGAG
HPRT_E6-142 chr22 23199165 0.1 cTggAgTCCAgAGATGGTCATGG
HPRT_E6-143 chr6 17237684 0.1 GTAgAAaCCAgAGATGGaCAAGG
HPRT_E6-144 chr10 82243028 0.1 tTATAATaCAAAGgTGGTaATGG
HPRT_E6-145 chr15 43004167 0.1 cTATAATCaAAAGtaGGTCATAG
HPRT_E6-146 chr7 25485727 0.1 aTATttTCCAAAaATGGTCATAG
HPRT_E6-147 chr2 71429668 0.1 GTAaAATCCAAAGAgGacCAGGG
HPRT_E6-148 chr3 141311087 0.1 cctaAATCtAAAGATGGTCgGGG
Chr Position DNA Cleavage Score DNA seq at a cleavage sites
HPRT_E8-01 chrX 133632686 2.6 GAAGTATTCATTATAGTCAAGGG
HPRT_E8-02 chr11 93382674 1.3 GAAGcATTCATTATAGTCAAAGG
HPRT_E8-03 chr21 34111536 0.6 GAAGaATTCATTATAGaCAATGG
HPRT_E8-04 chr11 100880874 0.6 aAgcTATTCATTATAGcaAATGG
HPRT_E8-05 chr22 29285654 0.6 GAAGTtaATTCATTATAGaCAATGG
HPRT_E8-06 chr4 15866630 0.5 aAAGTATTaATTATAGTCAAGGA
HPRT_E8-07 chr2 53543615 0.5 GAAGTAT-CcTTATAGTCAgAAG
HPRT_E8-08 chr3 149876617 0.4 GAAGTAT-CATTATAGTCttGGG
HPRT_E8-09 chr8 71429233 0.4 GcAGTATTCATaATAGTCAAAAG
HPRT_E8-10 chrX 146032194 0.4 aAAGTATTtcaTATAGcCAAAGG
HPRT_E8-11 chr5 132311070 0.4 GAAtTATTCATcATAGcCAAAGG
HPRT_E8-12 chr3 36349740 0.3 tAAGTAaTCATTATAGTCAgATG
HPRT_E8-13 chr3 181655989 0.3 atAGTATTCATTATAGTaAcAGG
HPRT_E8-14 chr11 116029576 0.3 aAAaTATcCATTATAGTCttACG
HPRT_E8-15 chr10 131905650 0.3 GAAcTATTCATTATtaTCAACGG
HPRT_E8-16 chr9 89312308 0.2 GttGTATTCATTATAGTCAAGAG
HPRT_E8-17 chr4 178543184 0.2 atAGTATTCATTATAGTaAcAGG
HPRT_E8-18 chr12 72733535 0.2 agAGTATcCAccATAGTCAAGGG
HPRT_E8-19 chr1 45916291 0.1 GAAGTAcatcTTATAaTCAATGG
HPRT_E8-20 chr4 153599265 0.1 aAtGTATTCATTATAGgCAAGAG
HPRT -Exon8
62
(By Daesik Kim in Institute for Basic Science)
Figure 13. Genome-wide specificities of ABE7.10, BE3, and Cas9. (a-b) 
Genome-wide Circos plots for HEK2 (a) and RNF2 (b) sites obtained with intact 
genomic DNA (gray) and genomic DNA treated with ABE7.10/Endo V (blue), 
BE3ΔUGI/USER (red), or Cas9 (Green). Arrows indicate the two on-target sites. 
(c-d) Sequence logos were obtained using WebLogo by comparing DNA sequences
at Digenome-captured sites.
63
4. Validation of genome-wide ABE7.10 off-target effects
The base editing frequencies of the 7 ABE7.10 deaminases were measured 
at a total of 193 sites, including those with high sequence homology or with a 
cleavage score of at least 1.0, via deep sequencing (Figure 14a and Table 6). 
Single-nucleotide substitutions were not measurably detected with frequencies 
above noise levels (typically in the range of 0.1~1%) caused by sequencing errors 
at 173 sites. Among the other 20 validated sites, the 7 on-target sites were base-
edited at frequencies that ranged from 29% to 72%. The other 13 validated off-
target sites were edited much less efficiently, at frequencies that ranged from 0.1% 
to 7.8%. This result shows that Digenome-seq is sensitive enough to capture ABE 
off-target sites with very low editing frequencies that are near detection limits.
In parallel, Cas9-induced indel frequencies and BE3-induced substitution 
frequencies were also measured at the 193 sites to compare ABE7.10 with BE3 and 
Cas9. Unexpectedly, ABE7.10 activities were correlated more strongly with Cas9 
activities (R2 = 0.77) than with BE3 activities (R2 = 0.39). Among six sites edited at 
relatively high frequencies with ABE7.10 but poorly with BE3 (Base editing
frequencies of 0.001% or lower) (shown as red dots in Figure 14b), two sites had 
no cytosine within the BE3 editing window of several nucleotides. Seven sites 
were edited efficiently with ABE7.10 but not with Cas9 (indel frequencies of 0.001% 
or lower) (shown as red dots in Figure 14c). Among these, three sites (43% = 3/7)
had a single extra or missing nucleotide compared to their respective on-target sites, 
possibly forming a DNA or RNA bulge, respectively, when hybridized with their 
respective sgRNAs. Our group had also reported previously that such bulge-
64
forming sites are common among BE3 off-target sites (Kim et al., 2017a) but rare 
among Cas9 off-target sites (Kim et al., 2016). Among the 193 sites identified via 
Digenome-seq using ABE7.10, two or four sites were edited in cells at relatively 
high frequencies with BE3 or Cas9, respectively, but poorly with ABE7.10 
(substitution frequencies of 0.001% or lower) (shown as blue dots in Figure 14b, c), 
showing again that ABE7.10, BE3, and Cas9 can recognize different sets of off-
target sites in the human genome. 
65
a
b                                 c   
(With Daesik Kim in Institute for Basic Science)
Figure 14. Genome-wide off-target validations of ABE7.10, BE3, and Cas9. (a)
Base editing efficiencies at ABE7.10 off-target sites measured using targeted deep 
sequencing. PAM sequences are shown in blue. Mismatched bases are shown in red. 
66
Dashes indicate RNA bulges. Means ± s.e.m. were from three independent 
experiments. (b-c) Scatterplots showing correlations between ABE7.10-mediated 
substitution frequencies and BE3-mediated substitution frequencies (n = 23) (b) or 
between ABE7.10-mediated substitution frequencies and Cas9-mediated 
substitution frequencies (n = 32) (c) Pearson's correlation coefficient was used to 
determine the correlation. The blue and red dots indicate off-targets validated for 
Cas9 or BE3 but not for ABE7.10 and those validated for ABE7.10 but not for 
Cas9 or BE3, respectively. 
67
Table 6. Mutation frequencies of ABE7.10, BE3, and Cas9 at on-target and off-









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































5. Increasing ABE7.10 genome-wide specificities using 
modified sgRNAs, Sniper-Cas9 and Ribonucleoprotein 
delivery
To minimize or avoid ABE off-target activity, three different methods
were used, proven useful for reducing Cas9 and BE3 off-target effects: sgRNA 
modification (Cho et al., 2014; Fu et al., 2014; Kim et al., 2015; Kim et al., 2016; 
Tsai et al., 2015), use of Sniper-Cas9 (Lee et al., 2018b), an engineered Cas9 
variant obtained via directed evolution in E. coli, and delivery of RNPs in lieu of 
plasmids (Kim et al., 2017b; Kim et al., 2014; Rees et al., 2017),
First, I replaced standard GX19 sgRNAs with truncated sgRNAs (termed 
gX18 or gX17) (“g” and “G” represent, respectively, a mismatched and matched 
guanine) or extended sgRNAs containing one or two extra guanines at the 5′
terminus (termed gX20 or ggX20) and measured editing frequencies in HEK293T 
cells (Figure 15a and Figure 16a). Extended sgRNAs reduced ABE off-target 
activity at almost every site without sacrificing its on-target activity (Figure 16b,
Figure 16b, and Table 7). Thus, at the four validated off-target sites identified using 
a GX19 sgRNA targeted to HPRT exon 6, gX20 or ggX20 sgRNAs showed 2 to 26-
fold improvement in specificity ratios, compared to the conventional GX19 sgRNA 
(Figure 15b). By contrast, truncated sgRNAs reduced both ABE on-target and off-
target activity at most sites and exacerbated off-target effects at sites with 
mismatches at or near the 5’ terminus (shown by asterisks and heatmaps in Figure
15b and Figure 16b).
74
I also found that use of Sniper ABE7.10, in which Sniper-Cas9 in lieu of 
the wild-type SpCas9 was fused to the adenine deaminase moiety (Figure 17 and 
Table 8), or combining Sniper ABE7.10 with modified sgRNAs further reduced 
ABE off-target activity at many validated off-target sites (Figure 18). Delivery of 
ABE7.10 RNPs rather than plasmids improved the specificity of base editing by a 




(With Daesik Kim in Institute for Basic Science)
Figure 15. Reducing ABE7.10 off-target effects with modified sgRNAs. (a) 
Target DNA-complementary RNA sequences of conventional (GX19), truncated 
(gX18 or gX17), and extended (gX20 or ggX20) sgRNAs. (b) ABE7.10-mediated 
base-editing frequencies determined by targeted deep sequencing at the HPRT-
Exon 6 on- or off-target sites in HEK293T cells. The heatmap shows relative 
specificities of modified sgRNAs, compared to that of the GX19 sgRNA. 
76
Specificity ratios were calculated by dividing the specificity of sgRNA of interest 
(on-target frequency/off-target frequency) by the specificity of the GX19 sgRNA 





(With Daesik Kim in Institute for Basic Science)
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Figure 16. On- and off-target activity measured using modified sgRNAs. (a) 
Mean of base editing frequency when using modified sgRNAs targeted to HEK2, 
RNF2, TK_EphB4, TYRO3, WEE1, HPRT-exon6, and HPRT-exon8. All data are 
the results of targeted deep sequencing. (b) Off-target activities measured using 
modified sgRNAs at the TYRO3 and HPRT-exon8 sites. The red and blue 
characters indicate the mismatched nucleotides and PAM sequences, respectively. 
The heatmap shows relative specificities of modified sgRNAs, compared to that of 
the GX19 sgRNA. The specificity ratio was calculated using the following formula: 
specificity of modified sgRNAs (on-target frequency/off-target frequency)/ 
specificity of conventional sgRNAs (on-target frequency/off-target frequency). 
Means ± s.e.m. were from three independent experiments.
79
















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Figure 17. Increasing specificity using Sniper ABE7.10. On- and off-target 
activity and specificity ratio when using ABE7.10 and Sniper ABE7.10 at the 
HPRT-exon6, HPRT-exon8, HEK2, EphB4 and TYRO3 sites. The red and blue 
characters indicate the mismatched nucleotides and PAM sequences, respectively. 
The heatmap shows relative specificities of Sniper ABE7.10 compared to that of 
plasmid DNA encoding ABE7.10. The specificity ratio was calculated using the 
86
following formula: specificity of Sniper ABE7.10 (on-target frequency/off-target 
frequency)/ specificity of conventional ABE7.10 (on-target frequency/off-target 
frequency). Means ± s.e.m. were from three independent experiments.
87
Table 8. Mutation frequencies of ABE7.10 and Sniper ABE7.10 at on-target 
and off-target sites captured by Digenome-seq
(Continued)
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Untreated (+) ABE7.10 (+) Sniper ABE7.10
HEK2_001 chr19 35505485 20.1 GAACAC-AAGCAcAGACTGaAGG 0.17 0.17 0.16
HEK2_002 chr15 93557679 15.1 GAACACA-tGCATAGACTGCTAG 0.55 0.55 0.59
HEK2_003 chr4 53536209 14.7 GAAtACtAAGCATAGACTcCAGG 0.02 0.05 0.07
HEK2_004 chr4 90522183 14.3 GAACACAAtGCATAGAtTGCCGG 0.16 0.33 0.13
HEK2_005 chr1 167742859 13.4 aAACACAgAGCAcAGACTGCTGA 0.16 0.22 0.22
HEK2_006 chr10 43159340 13.4 aAACACAAAGaCATAGACcaCTGG 0.22 0.18 0.17
HEK2_007 chr5 87240613 8.9 GAACACAAAGCATAGACTGCGGG 0.31 72.76 75.92
HEK2_008 chr9 290167 6.6 aAACAtAAAGaATAGACTGCAAG 0.09 0.10 0.11
HEK2_009 chr3 28560566 5.8 GAACACAAAGtATAGAaTGCTAG 0.11 0.10 0.09
HEK2_010 chr1 175310138 5.1 GgACACAAAGCtTAGACTcCAGG 0.39 0.42 0.34
HEK2_011 chr13 87616351 4.9 GAAgAtAAAGCATAGACTctAGG 0.12 0.13 0.11
HEK2_012 chr10 87125365 4.6 aAACAtAAAGCATAGACTGCaAAG 0.24 0.23 0.22
HEK2_013 chr18 32279782 3.9 aAAtACAAAGCATAGACTaatATG 0.20 0.24 0.20
HEK2_014 chr2 192248363 3.5 GAACACAtA-CATAGACaGCTGG 0.02 0.03 0.00
HEK2_015 chr5 160202385 3.0 GAAaACAAAGCAaAGAaaGCAGG 0.17 0.21 0.22
HEK2_016 chr15 63236612 2.9 aAcacaAtAGCATAGACTGgaCTG
HEK2_017 chr20 23101377 2.7 atACACAgAGCAaAGACTGCAGG 0.20 0.22 0.18
HEK2_018 chrX 48317375 2.5 aAACAtAAAGCcTAGACTGaCGG 0.32 0.30 0.31
HEK2_019 chr19 49972515 2.2 aAAaACAAAGCgTAGACTGtGGG 0.37 0.36 0.43
HEK2_020 chr12 81785997 2.1 GgACAaAAAGCATAGACTcaAGG 0.15 0.13 0.12
HEK2_021 chr1 40461424 2.1 atACACACAAGCAcAGACTGCAGG 0.50 0.42 0.47
HEK2_022 chr15 92968604 2.1 GAACACAgcaCATAaACTGCAGG 0.19 0.20 0.24
HEK2_023 chr5 142142325 2.0 aAACACtAA-CATAGACTGCAGG 6.76 6.74 7.27
HEK2_024 chr5 131174461 1.7 aAAtACAAtGCATAGACTGCTAG 0.10 0.11 0.11
HEK2_025 chr1 36097072 1.4 GtAaACAAAGCATAGACTGaGGG 0.22 0.24 0.23
HEK2_026 chrX 132724931 1.3 GAACA-tAAtCAcAGACTGCTGG 0.23 0.19 0.22
HEK2_027 chr6 139353017 1.3 ccAaACAAAaCATAGACTGCTGG 0.40 0.39 0.41
HEK2_028 chrX 36949816 1.3 GAAaACAAAaCATAGAgTGCTGG 0.14 0.16 0.15
HEK2_029 chr17 2670110 1.2 aAtCAaAtAGCATAGACTGCATG 0.22 0.20 0.23
HEK2_030 chr13 91254877 1.2 GAACACAAAcatagtACTGaAGG 0.18 0.20 0.16
HEK2_031 chrX 138877515 1.2 aAACAgAAAGCATgGACTGCGGA 0.10 0.16 0.13
HEK2_032 chr13 113428466 1.1 cAAtACAAAGgATAGACTGCAGG 0.08 0.12 0.10
HEK2_033 chr15 41796089 1.1 agACACAcAGCAcAGACTGCAGG 0.18 0.21 0.20
HEK2_034 chr11 128508576 1.0 GAAttCAAAGCATAGAtTGCAGG 0.13 0.11 0.10
HEK2_042 chr3 33744669 0.7 GAAaACAAAcCAcAGACTGgGGG 0.20 0.21 0.24
HEK2_044 chr16 64198277 0.7 GAAtACAtAaCATAGACTGgGGG 0.00 0.00 0.00
HEK2_050 chr20 97640 0.5 GAAttCAAAGCATAGAtTGCAGG 0.12 0.13 0.13
HEK2_052 chr3 10835885 0.5 aAACACAtAGCAcAGcCTGCAGG 0.13 0.15 0.16
HEK2_065 chr18 56307002 0.4 aAgaACAAAaCATAGACTGCAGG 0.23 0.26 0.22
HEK2_079 chr5 126385455 0.3 ccACACcAAGCATAGACTtCTGG 0.12 0.09 0.13
HEK2_082 chr12 131431445 0.3 GgAgAgAgAGCATAGACTGCTGG 0.21 0.22 0.21
HEK2_092 chr1 237916998 0.2 tAACACAAAGacTAaACTGCAGG 0.10 0.10 0.11
HEK2_093 chr1 215323272 0.2 tAcCACgAAGCATAGACTGtAGG 0.12 0.10 0.09
HEK2_099 chr13 45266353 0.2 GgACAtAAAtCATAaACTGCTGG 0.12 0.14 0.10
HEK2_101 chr1 77190607 0.2 tcACACAAAcCATAGACTGaGGG 0.19 0.18 0.17
HEK2_105 chr19 5068807 0.2 tAtCAgAAAGCAcAGACTGCGGG 0.16 0.14 0.14
HEK2_106 chr12 54405073 0.2 GAACAacAAGgATAaACTGCCGG 0.27 0.29 0.30
HEK2_110 chr20 17801623 0.2 GAAtgCcAAGCATAaACTGCAGG 0.00 0.00 0.00
HEK2_119 chr19 32225924 0.2 GgACACAgAGtATAGACTGaGGG 0.10 0.12 0.13
HEK2_121 chr13 58440671 0.1 GAAttCAAAGCATgGACTGCAGG 0.09 0.11 0.10
HEK2_139 chr7 113235709 0.1 tAAaACAAAGaAcAGACTGCTGG 0.25 0.31 0.28
HEK2_145 chr14 88566211 0.1 GtAgAaAAAGtATAGACTGCAGG 0.15 0.14 0.15
HEK2




Chr Position DNA Cleavage Score DNA seq at a cleavage sites Untreated (+) ABE7.10 (+) Sniper ABE7.10
RNF2-1 chr1 210858376 7.3 tcaccaTTAGTCATTACCTGCTG 0.03 0.05 0.05
RNF2-2 chr1 185056773 4.4 GTCATCTTAGTCATTACCTGAGG 0.22 32.79 16.24
RNF2-3 chr17 53928598 4.3 AGTCATCTTAGTCATTAC-TGAGG 0.44 0.45 0.51
RNF2-4 chr6 143212078 4.1 GTaATaTTAGTCATTACCgGTGG 0.18 0.17 0.19
RNF2-5 chr17 17072075 3.6 GTCATCcTAGTCATTtaCTGGGG 0.98 0.94 0.89
RNF2-6 chr12 131619804 2.2 aTCAcCTTAGcCATTACCaGGGG 0.35 0.33 0.42
RNF2-7 chr9 102127746 1.4 GTCA-CTTAGTCATTgCCTGTGG 0.36 0.37 0.33
RNF2-8 chr15 92315580 1.0 GTCAcaTTAGcCATTACCTGTGA 0.32 0.35 0.27
RNF2-15 chr2 51894204 0.4 aTCATCTTcaTCATTACaTGAGG 0.29 0.27 0.26
RNF2-19 chr4 125521739 0.4 tTaATCTTAGTCATTACtTtTGG 0.22 0.23 0.24
RNF2-20 chr2 102668931 0.3 aTCATCaTcGTCATTAtCTGGGG 1.39 1.23 1.22
RNF2-24 chr1 111785389 0.3 tcCATCTcAcTCATTACCTGAGG 0.11 0.18 0.18
RNF2-27 chr6 5869239 0.3 GcCAcCTcAGTCATTAgCTGGGG 0.40 0.48 0.46
RNF2-41 chr18 62061226 0.2 aTtATtTTAGTCATTACCTtTGG 0.02 0.02 0.04
RNF2
Base editing frequency (%)
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Untreated (+) ABE7.10 (+) Sniper ABE7.10
TYRO3-1 chr15 76553332 4.3 GGCCACACTAGtGTTGCcGCTGG 0.64 3.04 3.12
TYRO3-2 chr15 41857272 3.4 GGCCACACTAGCGTTGCTGCTGG 1.17 72.66 68.95
TYRO3-3 chr20 45312757 2.0 GGCCACACcAGCcTTGCTGtCGG 11.24 11.54 11.48
TYRO3-4 chr5 173133468 0.8 GGCCAC--TAGCGTTGCTcCAGG 0.36 0.36 0.32
TYRO3-5 chr22 50686658 0.6 GGCCACACTgaCcTTGCTGCTGG 1.02 1.07 1.02
TYRO3-6 chr9 140109027 0.4 ttCCACAC-AGCtTTGCTGCTGG 0.68 0.63 0.61
TYRO3-7 chr17 17207899 0.3 GGCCAC-CTAGgGTTGCTGCTGG 0.54 0.44 0.76
TYRO3-8 chr11 99666699 0.2 ccaCcCtCTAGCaTTGCTGCTGG 0.00 0.00 0.00
TYRO3-9 chr11 27495183 0.2 cctaACACcAaCGTTGCTGCTGG 0.98 0.85 0.95
TYRO3-10 chr1 38684664 0.2 ctgagCtCTAGCaTTGCTGCTGG 0.16 0.18 0.07
TYRO3-11 chr3 22936710 0.1 GGCatataTAGCaTTGCTGCTGG 0.32 0.22 0.28
TYRO3-12 chr6 150629124 0.1 GaaCACACTAaCaTTGCTGtGGG 0.70 0.88 0.82
TYRO3
Base editing frequency (%)
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Untreated (+) ABE7.10 (+) Sniper ABE7.10
WEE1-1 chr1 234241713 11.1 tTaGAGATGTTCTATTAtTCCGG 0.80 0.73 0.76
WEE1-2 chr11 9610086 2.0 GTCGAGATGTTCTATTACTCTGG 0.35 58.59 53.38
WEE1-3 chr4 18855558 1.9 GagGAGATGcTCTATTACTCCGG 2.38 2.32 2.08
WEE1-4 chrX 42756785 0.7 aTCaAGATGaaCTATTACTCTGG 0.21 0.24 0.22
WEE1-5 chr1 215805743 0.4 GTgGAGATGTTaTgTTACTCTGG 0.18 0.17 0.17
WEE1-6 chr5 57863350 0.4 GaCataATGTTCTATTACTCAAG 0.76 0.96 0.88
WEE1-7 chr4 119010382 0.3 taatAGATGTTCTATTACTaAGG 0.12 0.12 0.11
WEE1-8 chr15 80845387 0.3 aTtaAGATGTTCTATTAaTaGGG 1.05 0.92 1.02
WEE1-9 chr13 87867165 0.2 cagctaATGTaaTATTACTCAGG 0.59 0.61 0.58
WEE1-10 chr4 107037600 0.2 aTCaAGATaTTCTATTACTgGGG 0.24 0.28 0.23
WEE1-11 chrX 136297269 0.2 tcttAtATtTTCTATTACTCAGG 0.23 0.21 0.13
WEE1-12 chr1 8500986 0.2 aTaGAGcaGTTaTATTACTCTGG
WEE1-13 chr11 71806684 0.2 GTaGAGATGTTCTcTaACTCAGG 1.45 1.50 1.65
WEE1-14 chr12 83599167 0.2 cTCttttatTTCTATTACTCTGG 0.00 0.00 0.00
WEE1-15 chr8 71394697 0.1 aatataATaTTCTATTACTCAGG 0.46 0.41 0.56
WEE1-16 chr8 86942319 0.1 caactataaTTCTATTACTCTGG 0.00 0.00 0.00
WEE1-17 chr1 61165563 0.1 GgCtActgtcTCTATTACTCAGG 0.18 0.17 0.13
WEE1-18 chr20 45730192 0.1 aTttAGATaTTCTATTACTCTGA 0.23 0.28 0.24
WEE1-19 chr8 134795474 0.1 cTttAagataTCTATTACTCTGG 0.32 0.45 0.32
WEE1-20 chr2 128238175 0.1 caaGAGAcGcTCTATcACTCAGG 0.81 0.97 1.13
WEE1-21 chr7 31677975 0.1 aaacAGcTGTTCTATTACTCAGG 0.21 0.24 0.25
No PCR
WEE1
Base editing frequency (%)
89
(Continued)
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Untreated (+) ABE7.10 (+) Sniper ABE7.10
EphB4-01 chr7 100411300 10.3 GCAGAATATTCGGACAAACACGG 0.13 52.42 54.66
EphB4-02 chr5 81021421 8.0 GCAGAATATTaCaGACAAACtAGG 0.15 0.19 0.13
EphB4-03 chr15 47712791 4.1 GCAGAATATcaGGACAAACAATG 0.16 0.16 0.16
EphB4-04 chr11 123329727 2.4 aCAGAATATTCaGACAAtCACAG 0.26 0.27 0.21
EphB4-05 chr1 93047514 2.2 GCAGtA-AaTaaGACAAACAAGG 0.12 0.14 0.12
EphB4-06 chr15 51198151 1.9 aCAaAATATTCGGACAggCACGG
EphB4-07 chr18 29712895 1.8 GCAGAATtTaaGGACAAgCAAGG 0.13 0.14 0.14
EphB4-08 chr3 55670295 1.8 GCAGAATA--aGGACAAACATGG
EphB4-09 chr13 25919264 1.4 cagtAATATTCaGACtAAACATGG 0.27 0.24 0.26
EphB4-10 chr3 122057177 0.9 ttAatATATaaGGACAAACATGG 0.07 0.08 0.07
EphB4-11 chr1 26891812 0.8 aCAtAATATTCaaACAAACAGGG 0.14 0.13 0.14
EphB4-12 chr10 131074805 0.6 aatGAATAaagGGACAAACAGGG 0.18 0.19 0.22
EphB4-13 chr4 123425007 0.5 tCAG-ATATaaGGACAAACATGG 0.18 0.19 0.17
EphB4-14 chr5 60692862 0.4 GCtGAATATTgGGACAAtCATGG 0.12 0.10 0.13
EphB4-15 chr9 930844 0.4 GCAGttATAaaaaGACAAACAGGG 0.02 0.02 0.03
EphB4-16 chr9 29344386 0.4 aCAGAATATaaGaACAAAtATGG 0.05 0.07 0.08
EphB4-17 chr4 160752620 0.4 atAGAATAaTCaGACAAAaAAGG 0.09 0.08 0.08
EphB4-18 chr16 23706770 0.4 GCAG-ATAaagGGACAAACATGG 0.39 0.37 0.35
EphB4-19 chr11 117354211 0.3 GacagtgAaTaGGACAAACATGG 0.06 0.07 0.10
EphB4-20 chr14 90497703 0.3 tgAGAATATgCGGACAAACACAG 0.11 0.13 0.12
EphB4-21 chr2 68459706 0.3 atAGAATATTaGGACAAAtAGAG 0.00 0.16 0.15
EphB4-22 chr13 51951355 0.2 caAtAATAaaaGGACAAACATGG 0.08 0.11 0.08
EphB4-23 chr17 7777056 0.2 aCAGgATAaaaGGACAAAtATGG 0.06 0.10 0.07
EphB4-24 chr3 188431448 0.2 aCAGAtATAcgtaGACAAACAGAG 0.12 0.14 0.14
EphB4-25 chr12 11705824 0.2 atAGAATAagaaGACAAACATGG 0.30 0.38 0.35
EphB4-26 chr10 95697506 0.2 ttAGAATATTCctACAAACAAGG 0.07 0.09 0.08
EphB4-27 chrX 123665071 0.2 cCAtgtTATTCaGACAAACATGG
EphB4-28 chr16 75869847 0.2 GCAGAA-AaTaGGACAAtCACGG 0.17 0.14 0.14
EphB4-29 chr6 128784409 0.2 agAGAATATa-GGACAAACtTGG 0.22 0.22 0.21
EphB4-30 chr5 144297821 0.2 GCAGAAataTttGACAAACAAGG 0.13 0.13 0.09
EphB4-31 chr14 29760524 0.1 aaAGAATATa-GaACAAACAGGG 0.24 0.20 0.22
EphB4-32 chr1 36914336 0.1 aCAGAA-ATaCGaACAAACATGG 0.21 0.16 0.23
EphB4-33 chr21 26227853 0.1 aacaAATgcaaGGACAAACATGG 0.17 0.18 0.12
EphB4-34 chr13 63528393 0.1 aCActAT-TTaaGACAAACAGGG 0.17 0.15 0.13
EphB4-35 chr10 72516747 0.1 aCAGAActacgaGACAAACACGG 2.32 2.36 2.33
EphB4-36 chr7 20108292 0.1 GCAGA-TAccCaGACAAACAGGG
EphB4-37 chr1 89896856 0.1 taAGAATAT-aGGACAAACAGGA 0.13 0.12 0.12
EphB4-38 chr4 145533104 0.1 cCAGAATATTa-GACAAACATGG 0.22 0.25 0.24






Base editing frequency (%)
90
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Untreated (+) ABE7.10 (+) Sniper ABE7.10
HPRT_E6-01 chrX 133627607 29.0 GTATAATCCAAAGATGGTCAAGG 0.73 58.63 63.33
HPRT_E6-02 chr12 7468915 21.3 GTATAcatCcAAGATGGcCAGGG 0.14 0.17 0.15
HPRT_E6-03 chr3 10057621 17.0 GTATtA-CCAAAGATGGTCtGGG 0.22 0.34 0.28
HPRT_E6-04 chr22 39586062 12.7 GTATAATC-AAAGATGGcCcTGG 0.34 0.36 0.35
HPRT_E6-05 chr7 13928792 10.5 GTATtAT-CAAAaATGGTCAAGG 0.12 0.12 0.12
HPRT_E6-06 chr1 225831201 10.2 aTATAA-CCAAAGATGtTCACAG 0.26 0.29 0.23
HPRT_E6-07 chr17 53575925 9.3 aTATAATCttAAGATGGTCAAGG 0.12 1.45 0.19
HPRT_E6-08 chr12 13406973 9.0 aTATAATCCtAAGATGtTCATGG 0.12 0.11 0.10
HPRT_E6-09 chr14 27255077 6.1 GTATtATCCAAAGATGacCAGAG 0.12 0.12 0.15
HPRT_E6-10 chr7 85914581 5.6 aTAcAATCCAAAGtTGGTCtGGG 0.09 0.11 0.11
HPRT_E6-11 chr3 9906633 4.7 aTATAttaCCAAAGATGGTCtGGG 0.26 0.32 0.24
HPRT_E6-12 chr8 125496169 4.5 GTAgAATCCAtAGATGGaCAGGG 0.18 0.18 0.16
HPRT_E6-13 chr17 10064482 4.3 GTATtA-CCAAAGATGGTCATGG 0.12 1.19 0.23
HPRT_E6-14 chr2 53374352 4.3 GTAcAATCaAAAGATGaaCAAGG 0.14 0.12 0.16
HPRT_E6-15 chr4 102026801 4.1 aTATtATCCAAAGATGGagtTGG 0.04 0.03 0.04
HPRT_E6-16 chr6 19070067 3.8 aTgTAtTCCAAAGATGGTCAGGG 0.07 0.19 0.07
HPRT_E6-17 chr6 7761387 3.7 aagTAATCCAAAGATaGTCtTGG 0.12 0.12 0.12
HPRT_E6-18 chr12 59613203 3.6 GTATAAcCCAAAGAaaGTaATGG 0.25 0.26 0.20
HPRT_E6-19 chr16 20336811 3.6 aTATAtATtCcAAGATGGTtcTGG 0.07 0.07 0.08
HPRT_E6-20 chr4 136809212 3.5 tTATAATCCAAAGAaGGcCAAGG 0.14 0.10 0.13
HPRT_E6-21 chr12 117915656 3.5 GTATctAcCCAAAGATGtTCATGG 0.07 0.08 0.07
HPRT_E6-22 chr14 45005861 3.4 GTATAAT--AAAGATGGTCAAGG 0.12 0.15 0.12
HPRT_E6-23 chr14 104033102 3.3 aTAgAtTCCAAAGATGGaCATGG 0.08 0.08 0.07
HPRT_E6-24 chr11 93731924 3.1 cTATAATCtAAAaATGGTCAAGG 0.11 0.12 0.12
HPRT_E6-25 chr13 75257165 2.9 GTATAtTagAAAGATGGTCATGA 0.09 0.08 0.09
HPRT_E6-26 chr15 54911620 2.8 GgATAATCaAAAGATGGaCtTGG 0.09 0.07 0.07
HPRT_E6-27 chrX 6849511 2.6 aTATAATgCAAAGcTGGTCACGG 0.46 0.45 0.45
HPRT_E6-28 chr11 87526371 2.5 aTAcAATCCAAAGATatTCtAGG 0.13 0.13 0.14
HPRT_E6-29 chr3 19652583 2.4 GTATAATCCAAAGgTGGcCtAGG 0.28 0.27 0.29
HPRT_E6-30 chr17 45009128 2.4 aTATAATCCAtAGAaGGTCAAGA 0.27 0.30 0.30
HPRT_E6-31 chr8 9090663 2.3 GatatAatacAAGATGGaCAAGG 0.15 0.18 0.12
HPRT_E6-32 chr12 6810501 2.2 GgATAATCCAAAGATGGTgcAAG 0.23 0.24 0.20
HPRT_E6-33 chr6 118233456 1.5 aTATAAaCCAAAGATcGTtAAGG 0.22 0.24 0.27
HPRT_E6-34 chr14 85667729 1.4 tctcccTCCAAAGAaGGTCACGG 0.00 0.00 0.00
HPRT_E6-35 chrX 110551547 1.4 tTATAgTCCAAAGgaaGTCAGGG 0.10 0.09 0.09
HPRT_E6-36 chr8 18630339 1.2 tatTtATCCAAAGATGGTCtAGA 0.09 0.11 0.08
HPRT_E6-37 chr12 45338334 1.1 aTATAtaCCAAAGgTaGTCATGG 0.02 0.06 0.09
HPRT_E6-38 chr7 135056752 1.1 aggagATCCAAAGATGGTCAAGG 0.21 0.22 0.21
HPRT_E6-39 chr9 82090375 1.1 acATAgTCCAAAtATGGaCAGGG 0.04 0.04 0.02
HPRT_E6-40 chr12 103187212 1.0 GTATAtAattcAAGATGGTCAGGA 0.23 0.23 0.28
HPRT_E6-41 chr12 58996606 1.0 GaATAAgCCAAAGATGGTCAGTG 0.06 0.13 0.16
HPRT_E6-52 chr12 29153372 0.7 GTATttTCCAAcGATGGTCATGG 0.00 0.00 0.00
HPRT_E6-81 chr11 44024764 0.4 GTATAAgCCAAAGcaGGTCACGG 0.13 0.18 0.15
HPRT-Exon6
Base editing frequency (%)
Chr Position DNA Cleavage Score DNA seq at a cleavage sites Untreated (+) ABE7.10 (+) Sniper ABE7.10
HPRT_E8-1 chrX 133632686 2.4 GAAGTATTCATTATAGTCAAGGG 0.03 70.09 71.15
HPRT_E8-2 chr11 93382674 1.3 GAAGcATTCATTATAGTCAAAGG 0.11 10.33 3.53
HPRT_E8-3 chr21 34111536 0.6 GAAGaATTCATTATAGaCAATGG 0.17 0.17 0.19
HPRT_E8-4 chr11 100880874 0.6 aAgcTATTCATTATAGcaAATGG 0.05 0.03 0.06
HPRT_E8-5 chr22 29285654 0.6 GAAGTtaATTCATTATAGaCAATGG 0.08 0.08 0.10
HPRT_E8-6 chr4 15866630 0.5 aAAGTATTaATTATAGTCAAGGA 0.04 0.10 0.09
HPRT_E8-7 chr2 53543615 0.5 GAAGTAT-CcTTATAGTCAgAAG 0.16 0.16 0.14
HPRT_E8-8 chr3 149876617 0.4 GAAGTAT-CATTATAGTCttGGG
HPRT_E8-9 chr8 71429233 0.4 GcAGTATTCATaATAGTCAAAAG 0.07 0.06 0.04
HPRT_E8-10 chrX 146032194 0.4 aAAGTATTtcaTATAGcCAAAGG 0.11 0.11 0.12
HPRT_E8-11 chr5 132311070 0.4 GAAtTATTCATcATAGcCAAAGG 0.05 0.07 0.05
HPRT_E8-12 chr3 36349740 0.3 tAAGTAaTCATTATAGTCAgATG 0.14 0.15 0.13
HPRT_E8-13 chr3 181655989 0.3 atAGTATTCATTATAGTaAcAGG 0.05 0.05 0.03
HPRT_E8-14 chr11 116029576 0.3 aAAaTATcCATTATAGTCttACG 0.26 0.25 0.25
HPRT_E8-15 chr10 131905650 0.3 GAAcTATTCATTATtaTCAACGG 0.04 0.05 0.06
HPRT_E8-16 chr9 89312308 0.2 GttGTATTCATTATAGTCAAGAG 0.11 0.11 0.10
HPRT_E8-17 chr4 178543184 0.2 atAGTATTCATTATAGTaAcAGG 0.09 0.09 0.08
HPRT_E8-18 chr12 72733535 0.2 agAGTATcCAccATAGTCAAGGG 0.04 0.15 0.05
HPRT_E8-19 chr1 45916291 0.1 GAAGTAcatcTTATAaTCAATGG 0.05 0.04 0.07
HPRT_E8-20 chr4 153599265 0.1 aAtGTATTCATTATAGgCAAGAG 0.08 0.05 0.05
No PCR
HPRT-Exon8
Base editing frequency (%)
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Figure 18. Increasing specificity of ABE7.10 by combining Sniper ABE7.10 
with modified sgRNAs. On- and off-target activity and specificity ratio using 
ABE7.10 and Sniper ABE7.10 with modified sgRNAs at the HPRT-exon6 and 
HPRT-exon8 sites. The red and blue characters indicate the mismatched 
nucleotides and PAM sequences, respectively. The heatmap shows relative 
specificities of Sniper-ABE7.10 with modified sgRNAs compared to that of 
ABE7.10 and GX19 sgRNAs. The specificity ratio was calculated using the 
92
following formula: specificity of ABE7.10 (on-target frequency/off-target 
frequency)/ specificity of Sniper ABE7.10 with modified sgRNAs. (on-target 
frequency/off-target frequency). Means ± s.e.m. were from three independent 
experiments.
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Figure 19. Specificity of ABE7.10 depending on plasmid delivery or RNP 
delivery. On- and off-target activity and specificity ratio when delivering plasmid 
or RNP at the HPRT-exon8, HPRT-exon6, HEK2, EphB4 and TYRO3 sites. The red 
and blue characters indicate the mismatched nucleotides and PAM sequences, 
respectively. The heatmap shows relative specificities of ABE7.10 RNP delivery 
compared to that of plasmid DNA delivery encoding ABE7.10. The specificity ratio 
was calculated using the following formula: specificity of RNP delivery (on-target 
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frequency/off-target frequency)/ specificity of plasmid delivery (on-target 




If the existing CRISPR/Cas9 system has been used primarily for genetic 
knockout studies, the CRISPR RNA-guide base editor has been recently reported to 
be able to introduce more sophisticated and highly efficient point mutations 
(Gaudelli et al., 2017; Hess et al., 2016; Jiang et al., 2018; Komor et al., 2016; Li et 
al., 2018b; Ma et al., 2016b; Nishida et al., 2016). ABEs developed by directed 
evolution methods following several CBE types have been reported and the scope 
of studying human diseases has been broadened. 
In order to increase the efficiency of the base editor system to be more 
widely used, there have also been studies such as using an ancestral sequence of 
deaminase or giving a selection pressure (Koblan et al., 2018; Zafra et al., 2018). In 
addition, as in the previous reports (Koblan et al., 2018; Staahl et al., 2017; Zafra et 
al., 2018), this study confirms that it is also possible to optimize codon usage for 
the organism in which the base editor operates, for increasing protein expression or 
to change the type and number of NLSs, especially in cell lines expressing base 
editor constructs weakly.
I also compared the activity of the lower version of ABEs. It was 
confirmed that the activity ranking of varies according to the evolved version of 
TadA in HeLa and HEK293T cells. The activity of ABE7.10 was always best and 
the activity of ABE6.3 or ABE7.9 varied depending on the target site and cell type. 
I found that codon usage is important for other versions as well as ABE7.10, which 
is known to be the most active and widely used. Efficiency of ABE variants may 
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vary when used with various mismatched sgRNAs, so it may be helpful to use 
different versions of ABEs than only ABE7.10 if someone wants to reduce the 
efficiency of the off-target versus on-target at some target sites.
Newly known ABEs had to be proven to be genome-wide specific in order 
to be more widely used. I could confirm that mismatched sgRNAs would have 
different off-target effects from Cas9 nucleases or BE3, so the method of proving 
the accuracy only for ABEs was needed. To do this, Digenome-seq method, which
identifies and captures DNA DSBs that are caused by Cas9 nucleases, was 
modified (Kim et al., 2015). One strand was cleaved by Cas9 nickases of ABEs and 
the other strand was cut using Endo V or hAAG/Endo VIII combination, which can 
recognize and inosine, the deamination product of A. After digesting the DNA of 
both strands, the whole genome was sequenced and aligned to the reference 
genome, and the Digenome cleavage score was calculated to obtain a potential off-
target list.
From Digenome-seq results of 7 target sites, I could confirm that ABEs (8 
± 4 per target site, on average) were more specific than Cas9 (70 ± 30 sites (Kim et 
al., 2016)) and showed a potential off-target different from that of CBEs, And,
unlike Cas9, DNA and RNA bulge off-targets were allowed as CBEs (Kim et al., 
2017a). Also, I could validate that Digenome-seq could detect off-target sites with 
a substitution frequency of 0.1% or more in human cells.
To increase the specificity, I tested three methods. The first method was to 
modify 5 'of sgRNA (Cho et al., 2014; Fu et al., 2014; Kim et al., 2015; Kim et al., 
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2016; Tsai et al., 2015). The second method was to use Sniper-Cas9, which was 
evolved to be specific instead of wild type Cas9 (Lee et al., 2018b). The last 
method was to use RNP delivery method instead of plasmid DNA delivery method
(Kim et al., 2017b; Kim et al., 2014; Rees et al., 2017). Guide RNA modification is 
the truncation at 20-nt spacer length or extension of the spacer length of sgRNA
with additional G or GG. In the case of truncation, the on-target activity was 
decreased as well and higher activity was observed in some off-targets. However, 
in the case of extended sgRNAs (gX20 or ggX20), it was confirmed that the off-
target effects were decreased while the on-target activity remained unchanged, so
the specificity was increased.
Sniper-Cas9 is Cas9 which improves specificity like existing enhanced 
specificity Cas9 (eSpCas9), Cas9-high fidelity (Cas9-HF) or Hypa Cas9 specificity
(Chen et al., 2017; Kleinstiver et al., 2016; Slaymaker et al., 2016) but it is made 
by selection system of random library unlike existing other specific Cas9 variants
made by rational design. Unlike other specific Cas9 variants, Sniper-Cas9 has the 
advantage of working well with modified sgRNAs, so I used it for ABEs instead of 
wild type Cas9 and found that the specificity can be increased up to 5 times or 
more. If working with modified sgRNAs, it is possible to increase the specificity
more than 80-fold.
In the case of RNP delivery methods, no external DNA is needed so GMO 
issues can be avoided in some cases (Kanchiswamy et al., 2015). In addition, since 
it has been reported that the off-target effects are low due to the short duration of 
expression due to the DNA-free delivery (Kim et al., 2014; Rees et al., 2017), the 
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RNP delivery method was used to increase the specificity and could be increased to 
about 7 times.
In summary, I showed, codon optimization and the number of NLSs is 
important for ABEs activity. Also, using mismatched sgRNAs, Digenome-seq
capture, and validation off-targets in human cells, it was confirmed that ABE7.10, 
BE3, and Cas9 can recognize different sets of off-target sites in the human genome, 
calling for independent assessments of each tool. The seven ABE7.10 deaminases 
were reasonably specific, catalyzing A-to-G conversions in vitro at a limited 
number of sites in the human genome. I also showed that use of modified sgRNAs, 
RNPs, and Sniper ABE7.10 can reduce or avoid ABE off-target activity.
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국문초록
CRISPR/Cas9 시스템은 최근 10 년간 생명 공학 분야에서 가
장 널리 쓰이는 기술 중 하나이다. CRISPR 시스템은 박테리아 면역 체
계에서 유래한 것으로 현재는 프로그래밍 가능한 핵산 분해 효소, 즉 유
전체 교정 도구로서 이용된다. 이 유전체 교정 도구는 DNA 이중 가닥
절단을 만든 후 세포 복구 기작을 이용하여 유전자를 망가뜨릴 수 있을
뿐 아니라 외부 유래 DNA와 함께 작용하여 유전자를 삽입하는 데에도
사용될 수 있다. 기존의 CRISPR 시스템은 정교한 상동재조합 방법보다
는 비상동성 말단 접합 방법으로 복구가 일어나므로 주로 유전자를 망가
뜨리는 데 사용된다는 한계가 있다.
그러나 인간의 질병을 일으킬 수 있다고 알려진 돌연변이의 약
58%는 점 돌연변이다. 따라서 점 돌연변이를 도입하는 기술의 필요성이
제기되었고, 최근 이를 가능하게 하는 CRISPR 염기교정 유전자 가위가
개발되었다. CRISPR 염기교정 유전자 가위는 DNA 이중 가닥을 자르는
아미노산이 일부 비활성화된 Cas9 (Cas9 니케이즈)과 시토신/아데닌
탈아미노 효소로 이루어져 있다. 시토신 염기교정 유전자 가위는 C:G
염기쌍을 T:A 염기쌍으로 바꿀 수 있으며, 아데닌 염기교정 유전자 가
위는 아데노신을 탈아미노화 하여 A:T 염기쌍을 G:C 염기쌍으로 전환
시킬 수 있다. 이러한 염기교정 유전자 가위는 최근 여러 종류가 독립적
으로 보고되었으며 박테리아, 인간 세포, 동물 및 식물 등에 적용되고
112
있지만 염기 교정 유전자 가위, 특히 아데닌 염기 교정 유전자 가위의
특이성에 대한 연구는 기존에 없었다.
이 논문에서는 우선 아데닌 염기 교정 유전자 가위의 염기 교정
효율이 코돈 사용에 따른 발현량에 영향을 받고 핵 위치 신호의 수가 많
아진다면 효율이 높아질 수 있다는 것을 입증하였다. 또한 DNA 이중
가닥 절단 위치를 인식하는 방법으로 알려진 기존의 Digenome-seq 방
법을 변형하여 아데닌 염기 교정 유전자 가위의 비표적 효과를 검증하는
방법을 소개하였다. 아데닌 염기 교정 유전자 가위의 비표적 효과는
Cas9 DNA 이중 가닥 절단효소나 시토신 염기 교정 유전자가위의 비표
적 효과와는 다르다는 것을 확인할 수 있다. 이러한 비표적 효과가 인간
세포에서도 실제로 발생하는지를 확인하고 마지막으로는 DNA와 염기쌍
을 이룰 수 있는 spacer 염기 서열의 길이를 변형시킨 sgRNAs를 사용
하거나 와일드 타입의 Cas9 니케이즈 대신 특이적이라고 알려진
Sniper Cas9 니케이즈를 사용하는 방법 외에도 플라스미드 DNA 전달
대신 단백질과 전사된 RNA 형태로 전달하는 방법이 아데닌 염기 교정
유전자 가위의 특이성을 증가시키는데 효과적이라는 것을 보였다.
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